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Abstract 
The recent liberalisation of cannabis regulation has increased public and scientific 
debate about its potential benefits and risks. A key focus has been the extent to which 
cannabidiol (CBD) might influence the acute effects of delta-9-tetrahydrocannabinol 
(THC), but this has never been reviewed systematically. In this systematic review of 
how CBD influences the acute effects of THC we identified 16 studies involving 466 
participants. Ten studies were judged at low risk of bias. The findings were mixed, 
although CBD was found to reduce the effects of THC in several studies. Some studies 
found that CBD reduced intense experiences of anxiety or psychosis-like effects of 
THC and blunted some of the impairments on emotion and reward processing. 
However, CBD did not consistently influence the effects of THC across all studies and 
outcomes. There was considerable heterogeneity in dose, route of administration and 
THC:CBD ratio across studies and no clear dose-response profile emerged. Although 
findings were mixed, this review suggests that CBD may interact with some acute 
effects of THC. 
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1. Introduction 
In the last decade, there have been substantial changes to cannabis regulation, with 
many countries adopting a more permissive stance towards medical and recreational 
use (Kilmer, 2017). The World Health Organisation recently proposed the 
rescheduling of cannabis and its removal from the schedule IV category in light of the 
drug's medicinal properties (Mayor, 2019). Cannabis and cannabinoids have the 
potential to treat several medical conditions including chronic pain, treatment-resistant 
epilepsy, and nausea and vomiting due to chemotherapy (T. P. Freeman, Hindocha, 
Green, & Bloomfield, 2019). However, over 60 years of prohibition and associated 
regulatory barriers to researching this field (Nutt, 2015) means there are significant 
gaps in our knowledge about the clinical benefits and potential harms (Hall, Hoch, & 
Lorenzetti, 2019). Recently, there has been renewed interest in whether the 
composition of the different cannabinoids within cannabis may improve its safety 
profile while enhancing medicinal efficacy (McPartland & Russo, 2014).  
The cannabis plant (Cannabis Sativa L.) produces over 140 different 
compounds known as phytocannabinoids and terpenoids (Hanuš, Meyer, Muñoz, 
Taglialatela-Scafati, & Appendino, 2016), many of which directly modulate the 
endogenous cannabinoid system in humans (Lu & Mackie, 2016). The 
endocannabinoid system consists of at least two types of cannabinoid receptors (CB1 
and CB2) and endogenous ligands (endocannabinoids such as anandamide and 2‐
arachidonoylglycerol) that bind to these receptors and ligand metabolic enzymes. 
Cannabinoid receptors are as abundant as glutamate, gamma-aminobutyric acid 
(GABA), or dopamine receptors in the brain (Katona & Freund, 2012), and 
consequently are involved in a wide range of functions including regulation of mood, 
memory and reward processing (Bossong, Jansma, Bhattacharyya, & Ramsey, 2014; 
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Curran et al., 2016). CB1 receptors are primarily located in central and peripheral 
neurons and mediate the release of transmitters at the synaptic terminal, including 
acetylcholine, noradrenaline, dopamine, 5‐hydroxytryptamine (5‐HT), GABA, 
glutamate, D‐aspartate and cholecystokinin. Inside and outside of the central nervous 
system, CB2 receptors are predominant in the immune system and have a role in 
altering the release of chemical messengers, cytokines, and the modulation of immune 
cell migration (Pertwee, 2008). 
Two of the most widely researched cannabinoids are delta-9-
tetrahydrocannabinol (THC), and cannabidiol (CBD), which have contrasting 
mechanisms of action and effect profiles. THC and CBD concentrations vary across 
different types of cannabis products used for recreational (T. P. Freeman et al., 2014) 
and medicinal purposes (T. P. Freeman et al., 2019). Although some strains of cannabis 
contain both THC and CBD in similar quantities, concentrations of THC in cannabis 
doubled over the past ten years (T. P. Freeman, Groshkova, et al., 2018). CBD content, 
which may attenuate the effects of THC, has become nearly obsolete in illicit samples 
of the drug across Europe and the USA (Chandra et al., 2019; Potter, Hammond, 
Tuffnell, Walker, & Di Forti, 2018).  
1.1. Pharmacology of THC and CBD 
The pharmacology of THC, although reasonably well understood, is complex. THC 
interacts with several pharmacological targets (see Pertwee and Cascio (2014) for a 
review). THC is a partial cannabinoid receptor agonist acting on both CB1 and CB2 
and can behave as both an agonist and antagonist at the CB1 receptor. Although THC 
acts primarily through the neuronal presynaptic CB1 receptors to inhibit ongoing 
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neurotransmitter release. Repeated administration of THC may give rise to tolerance 
to its effects and the action of endocannabinoids (Colizzi & Bhattacharyya, 2018; 
Pertwee, 2008).  
CBD differs from THC in several important ways. CBD has no intoxicating 
properties at typical doses (Pertwee, 2008). CBD has minimal direct activity at CB1 
and CB2 receptors, having low affinity for both receptor subtypes (Thomas et al., 
2007). Unlike THC, which acts at the orthosteric site of CB1 receptors, CBD is a 
negative allosteric modulator that can alter the potency and efficacy of the orthosteric 
ligand without activating the receptor (Hayakawa et al., 2008; Laprairie, Bagher, 
Kelly, & Denovan-Wright, 2015). This may explain preclinical findings which suggest 
that, when administered together, CBD may counteract some of the actions of THC, 
while also potentiating other actions of THC (McPartland & Russo, 2014). CBD has 
also been shown to modulate 5HT1A (Ross, 2007; Russo, Burnett, Hall, & Parker, 
2005) and PPARγ (Campos, Moreira, Gomes, Del Bel, & Guimaraes, 2012) as an 
agonist, GPR55 as an antagonist (Ryberg et al., 2007), and to inhibit the hydrolysis 
and reuptake of the Fatty Acid Amide Hydrolase enzyme (Bisogno et al., 2001).  
1.2.  Acute effects of THC  
When acutely administered, THC induces a broad range of transient and dose-
dependent effects. THC causes psychotropic effects of cannabis, inducing the “high” 
or “stoned” effect associated with its ingestion (Gaoni & Mechoulam, 1964). THC is 
associated with a dose-dependent increase in heart rate (Karniol & Carlini, 1973; 
Zuurman et al., 2008). Although many studies have investigated the subjective effects 
of THC, there has been considerable variation in doses, routes of administration and 
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outcomes used. THC induces appetitive effects including wanting more of the drug 
and liking the drug’s effects (Curran, Brignell, Fletcher, Middleton, & Henry, 2002). 
It  reduces anxiety at low doses, but increases anxiety at higher doses (Hunault et al., 
2009) and has been shown to robustly reduce alertness (Zuurman et al., 2008). 
However, these effects can vary between individuals and within individuals on 
different occasions of use (Green, Kavanagh, & Young, 2003). THC produces 
transient psychosis-like effects (D'Souza et al., 2004; Morrison & Stone, 2011; 
Morrison et al., 2009), which may be enhanced in individuals prone to psychosis 
(Mason et al., 2009). THC also interferes with several behavioural and cognitive 
processes impairing episodic memory, attention and working memory (Ranganathan 
& D’Souza, 2006; Volkow et al., 2016). Functional imaging studies have shown that 
THC disrupts the neural correlates of emotional processes, executive function and 
reward function (Bloomfield et al., 2018).  
1.3. Acute effects of CBD 
Originally believed to have a minimal effect due to its lack of subjective effects, CBD 
has recently received renewed interest for its potential therapeutic properties (Khoury 
et al., 2019; Zuardi, 2008). Few studies have investigated the acute effects of CBD, 
and the results of these studies have been mixed. Some studies report that low doses 
of CBD (30mg oral; 25mg IV respectively) has no intoxicating effects (Hollister, 1973; 
Perez-Reyes, Timmons, Davis, & Wall, 1973). However, in a small double-blind 
crossover study (n=7), Zuardi, Guimaraes, and Moreira (1993) found that CBD 
(300mg oral) acutely increased somnolence and reduced anxiety and two studies found 
that CBD (200mg oral; 400mg vaporised respectively) produced mood altering and 
subjective intoxicating effects (Leweke, Schneider, Radwan, Schmidt, & Emrich, 
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2000; Solowij et al., 2019). CBD (400-600mg oral) administered alone is also 
associated with anxiolytic effects (Crippa et al., 2011; Hundal et al., 2018; Zuardi et 
al., 1993), however, in a recent study of emotional processing tasks, CBD (300-900mg 
oral) induced minimal behavioural and subjective effects (Arndt & De Wit, 2017). 
CBD (32mg vaporised) has been shown to enhance consolidation of fear extinction 
learning in humans (Das et al., 2013), which suggests its effects on emotional 
processing may be nuanced and related to other cognitive processes. Several studies 
have investigated chronic administration of CBD for a range of therapeutic indications 
including as an antiepileptic, anxiolytic, antipsychotic and neuroprotective drug (for a 
review see White, 2019; and Whiting et al., 2015). 
1.4. The interaction between THC and CBD 
A much debated question is whether, when administered together, CBD interacts with 
THC’s effects. Some researchers have suggested that CBD can influence the effects of 
THC, increasing its clinical efficacy and reducing harmful effects (Ben-Shabat et al., 
1998; Bonn-Miller, ElSohly, Loflin, Chandra, & Vandrey, 2018; Russo & McPartland, 
2003). Some studies have demonstrated this effect, for example: evidence from survey 
data (Schubart et al., 2011), and naturalistic hair analysis studies suggests that 
increased CBD content in cannabis may be protective against various memory-
impairing effects and psychosis-like experiences associated with cannabis use 
(Demirakca et al., 2011; Morgan & Curran, 2008; Morgan et al., 2011). Another 
naturalistic study, where cannabis users smoked their own cannabis which was later 
analysed for THC and CBD content, found that high CBD content was associated with 
reduced impairment of verbal memory and a reversal of attentional bias towards 
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cannabis and food cues (Morgan, Freeman, Schafer, & Curran, 2010; Morgan, Schafer, 
Freeman, & Curran, 2010).  
Evidence from repeated dosing studies is more mixed. One parallel group, randomised 
controlled trial (n=177) study in patients with intractable cancer-related pain showed 
that a combination of THC (2.7 mg) and CBD (2.5mg) in an oromucosal spray 
produced a significant improvement on a pain rating scale compared to placebo, 
whereas the THC (2.7mg) group showed no significant change. Twice as many 
patients (43% of patients) taking THC and CBD showed a 30% pain reduction (on a 
0-10 Numerical Rating Scale) from baseline compared to placebo (21% of patients) 
(Johnson et al., 2010). Others, however, have found THC alone to be more clinically 
effective than a combination of the two in chronic pain, fibromyalgia and neuropathic 
pain (Notcutt et al., 2004; van de Donk et al., 2019; Wade, Robson, House, Makela, & 
Aram, 2003).  
Much uncertainty also exists around whether CBD alters the pharmacokinetic 
profile of THC (Lucas, Galettis, & Schneider, 2018). For example, while Agurell et 
al. (1981) found that co-administration of CBD with THC did not alter the 
pharmacokinetics of THC, van de Donk et al. (2019) showed that plasma 
concentrations of THC were higher than expected when a treatment containing both 
THC (13.4mg) and CBD (17.8mg) was administered compared to a treatment 
containing THC (22.4mg) and CBD (1mg).  
Previous non-systematic reviews have suggested that CBD may attenuate the 
acute harmful effects of THC (Colizzi & Bhattacharyya, 2017; Englund, Freeman, 
Murray, & McGuire, 2017; Niesink & van Laar, 2013) while potentiating its positive 
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effects (Russo, 2019; Russo & Guy, 2006). One systematic review investigating 
whether CBD has antipsychotic effects found that CBD may offset the psychosis-like 
effects of THC (Iseger & Bossong, 2015). Although several narrative reviews have 
discussed the question of whether CBD interacts with THC when administered 
together acutely, this question has never been reviewed systematically. This systematic 
review aimed to establish how CBD influences the acute effects of THC in humans. 
2. Methods 
2.1. Protocol and registration  
This review was conducted according to Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) guidelines (Liberati et al., 2009) and a 
checklist is provided in Appendix A. The protocol (Appendix B) and registration for 
the current systematic review was prospectively registered (PROSPERO: 
CRD42019126994) on 28th February 2019 (A. M. Freeman et al., 2019). 
2.2. Eligibility criteria  
2.2.1.1. Inclusion criteria 
a) A condition or group in which THC is acutely administered. 
b) A matched condition or group where the same dose of THC is acutely 
administered together with cannabidiol (CBD), under experimental conditions.   
c) THC must be delivered via the same route of administration in both conditions, 
as different routes (e.g., oral THC alone versus intravenous THC combined 
with CBD) may lead to a different profile of effects related to different 
pharmacokinetics and metabolism of the drug, as well as the interaction 
between the compounds. 
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d) The studies must include either a placebo condition or a control condition 
where there is no drug administered, for example, a pre-drug measurement or 
baseline measurement. This is necessary to evaluate the acute effects of THC. 
e) The included papers must be peer-reviewed. 
f) Articles must be published in English. 
2.2.2. Exclusion criteria 
a) Conference extracts or abstracts, theses, reviews, supplements, editorial 
reports, correspondence, non-peer reviewed material, e.g. books extracts, 
notes, and letters.  
b) Studies where there was no matched dose and route of administration for THC, 
with and without CBD. 
c)  Repeated dosing studies. 
d)  Studies where the statistical analysis did not directly compare either 1) THC 
alone to a matched dose of THC with CBD, or 2) THC to placebo, and a 
matched dose of THC with CBD and placebo. 
e) Studies not including humans. 
 
2.3. Information sources  
A systematic search was conducted on 28th February 2019 using the following 
electronic bibliographic databases: MEDLINE, EMBASE, PsycINFO, and CINAHL 
Plus. The search strategy included only terms relating to or describing the intervention 
(THC and CBD). The terms were combined with the Ovid filter for human studies and 
studies published in English. The search terms were adapted for use for each 
bibliographic database and run in combination with database-specific filters for human 
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trials and peer-reviewed articles, where these were available. The search terms and 
results are provided in Appendix C.  
2.4. Study selection  
The titles and abstracts of studies retrieved using the search strategy, and those from 
additional sources, were screened independently by two reviewers (AF and RL) to 
identify studies that potentially met the inclusion criteria outlined above. The full text 
of these potentially eligible studies was retrieved and independently assessed for 
eligibility by two review team members (AF and KP). Any disagreement between 
them over the eligibility of particular studies was resolved through discussion with a 
third reviewer (TF). 
2.5. Data collection process and data items 
A standardised, pre-piloted form (in Microsoft Excel) was used to extract data from 
the included studies for assessment of study quality and evidence synthesis (Appendix 
D). This form was adapted from the Cochrane Collaboration’s Data collection form 
for intervention review – randomised controlled trials (RCT). Through the 
development process, some irrelevant sections were removed from the original form 
and new sections added. The extracted information included: study setting; study 
population and details of the dose and route of administration for THC and CBD; 
THC:CBD ratio; study methodology; recruitment and study completion rates; 
outcomes and times of measurement; information for the assessment of the risk of bias. 
Two reviewers (AF and KP) extracted the data, and discrepancies were resolved 
through discussion with a third reviewer (CH) where necessary. A subset of the 
extracted data was randomly checked by another reviewer (CH).  
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2.6. Risk of bias in individual studies  
Two reviewers (AF and KP) independently assessed the risk of bias in included studies 
by considering the criteria set out by the Cochrane’s Risk of Bias (RoB2) assessment 
tools as appropriate for the study design (Higgins et al., 2011). Disagreements between 
the reviewers over the risk of bias in particular studies were resolved by discussion, 
with the involvement of a third review author (CH) where necessary.  
2.7. Risk of bias across studies  
This review assessed the risk of publication bias by considering the different types of 
bias laid out in the Cochrane Handbook for Systematic Reviews of Interventions 
(Higgins & Green, 2008; Higgins et al., 2016).  
2.8. Summary measures  
It was acknowledged that the included studies would have investigated a variety of 
outcome measures and therefore this review planned to take an inclusive approach and 
report all outcomes where the effects of THC alone were compared to the effects of 
the same dose of THC combined with CBD.  
3. Results  
The initial search on 28th February 2019 identified 1808 records, of which 601 were 
duplicates and excluded. Four additional articles were identified as they were 
published after the initial search. The abstract and title of 1211 articles were reviewed, 
and 47 articles were considered potentially relevant and subject to full-text searching. 
Study selection procedures yielded 23 published articles reporting on 16 studies which 
met the inclusion criteria. A table summarising the excluded studies is provided in 
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Appendix E. Figure 2 displays a flow diagram of the reasons for exclusion at each 
stage (Appendix F).   
3.1. Study characteristics 
Altogether, 16 studies reported in 23 articles were included in this review (Arkell et 
al., 2019; Bhattacharyya et al., 2010; Bird et al., 1980; Dalton, Martz, Lemberger, 
Rodda, & Forney, 1976; Englund et al., 2013; T. P. Freeman, Pope, et al., 2018; Guy 
& Robson, 2003; Haney et al., 2016; Hindocha et al., 2015; Hollister & Gillespie, 
1975; Hunt, Jones, Herning, & Bachman, 1981; Juckel, Roser, Nadulski, Stadelmann, 
& Gallinat, 2007; Karniol, Shirakawa, Kasinski, Pfeferman, & Carlini, 1974; Lawn et 
al., 2016; Morgan et al., 2018; Nadulski et al., 2005; Nicholson, Turner, Stone, & 
Robson, 2004; Roser et al., 2009; Roser et al., 2008; Stadelmann et al., 2011; Zuardi, 
Shirakawa, Finkelfarb, & Karniol, 1982). Table 1 provides details of each study’s 
aims, the participants and their cannabis use history, the intervention groups, and 
outcome measures.  
All studies were experimental human laboratory studies. Only three studies 
(Bird et al., 1980; Englund et al., 2013; Karniol & Carlini, 1974) used parallel group 
designs, and the rest used a crossover design. Study sample sizes varied between 4 and 
155 participants, with a total of 466 participants. Some studies were explicitly designed 
to evaluate drug safety and pharmacokinetics, and were therefore not powered to detect 
treatment effects (Guy & Robson, 2003; Hunt et al., 1981). One parallel group study 
(Karniol et al., 1974) and five crossover-design studies (Bhattacharyya et al., 2010; 
Dalton et al., 1976; Hunt et al., 1981; Nicholson et al., 2004; Zuardi et al., 1982) had 
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less than 10 participants (4-8) per treatment cell and therefore may not be powered to 
detect smaller effect sizes (Simmons, Nelson, & Simonsohn, 2011). 
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Table 1 Summary of Study Characteristics and Findings 
Study and 
location 
Aim Participants Design *Intervention Outcomes Main findings 
Risk of 
Bias 
Arkell et al. 
(2019), 
Australia  
To compare the 
subjective, cognitive, 
and driving-related 
effects of vaporized 
THC, and THC and 
CBD combined. 
14 healthy volunteers (three 
women; 11 men) 21-38 
years with self-reported 
cannabis use ≤ 2 times a 
week for three months and 
lifetime use ≥ 10 times 
Three participants did not 
complete, one withdrew, 
one did not comply with the 
protocol and another was 
discharged due to elevated 
blood pressure and heart 
rate. No illicit drugs for 
duration of the study. 
Breathalyser and oral fluid 
screening for recent alcohol 
and drug use on each day. 
Placebo-
controlled, double-
blind, crossover 
study across three 
treatment 
conditions. 
Randomized and 
counterbalanced 
order.  
Vaporised THC  
3.75 mg  + 
CBD 13.75 mg; 
vaporised THC 
13.75 mg + 
CBD < 1.25 
mg; vaporised 
Placebo < 1.25 
mg THC/CBD 
 
DAT driving 
simulation task, 
DSST, PASAT, 
pharmacokinetics, 
self-rating of 
subjective 
intoxicating effects.  
Peak plasma concentrations of 
THC higher in THC+CBD  
No difference in self-rated 
subjective intoxication or 
confidence to drive for THC 
and THC+CBD =  
STAI and anxious self-rating 
was increased in both  THC and 
THC+CBD at 15 mins but not 
THC+CBD at 1 hour =/ 
Car following task both THC 
and THC+CBD impaired SDLP 
= 
THC with CBD impaired 
performance on the DAT 
compared to THC or placebo  
Low 
Bhattachary
ya et al. 
(2010), 
United 
Kingdom 
To investigate whether 
pre-treatment with 
CBD can prevent THC 
from provoking 
psychotic symptoms. 
Six healthy volunteers 
(three women; three  men) 
21-42 years, with mean 
lifetime self-reported 
cannabis use 150 times; 
minimal exposure to other 
illicit drugs. Negative 
urinary drug screen before 
each testing session. 
Placebo-
controlled, double-
blind, crossover 
study, across two 
treatment 
conditions. 
Pseudo-
randomisation. 
Pre-treatment 
(T-5mins) 
intravenous 
CBD 5 mg 
followed by 
intravenous 
THC 1.25 mg; 
pre-treatment 
(T-5mins) 
intravenous 
Placebo 
PANSS, 
pharmacokinetics. 
 
No significant difference in 
blood levels of THC with or 
without pre-treatment with 
CBD = 
THC increases psychotic 
symptoms on PANSS in three 
participants; pre-treatment (T-
210 mins) with CBD but not 
placebo CBD blocks the 
emergence of these in all three 
volunteers  
Low 
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Bird et al. 
(1980)a,  
Australia  
To examine the effect 
of all of the possible 
combinations between 
ethanol and the major 
constituents of 
cannabis, in one 
experimental design. 
161 recruited (39 women; 
122 men, six excluded 
following breathalyser); 18-
36 years, whom 50% self-
reported cannabis use at 
least once a week; 
experience varied from 1-
13years, with a median of 
3.8 years. Breathalyser to 
confirm no presence of 
alcohol on test day.  
Placebo-
controlled, double-
blind, parallel 
study across 16 
treatment 
conditions. 
Randomly 
assigned to 
treatment group. 
Oral THC 
0.215 mg/kg + 
CBD 0.320 
mg/kg;  oral 
THC 0.215 mg; 
oral Placebo  
Auditory and 
complex reaction 
times, conjunctival 
hyperaemia, pulse 
rates, the pursuit-
rotor (errors and 
time off target), self-
rating of subjective 
intoxicating effects, 
standing steadiness 
(eyes open and 
closed), visual, 
VDA.  
When co-administered CBD 
did not modify the effects of 
THC, where THC reduced 
performance on perceptual, 
cognitive and motor function 
tests and increased pulse rate, 
conjunctival hyperaemia and 
subjective intoxication = 
Some 
concerns 
Dalton et al. 
(1976), 
United 
States  
To evaluate the 
interaction between 
THC and CBD in 
typical doses used by 
cannabis smokers. 
16 healthy volunteers 
(men) 21-24 years, with 
self-reported cannabis use 
at least once, but never 
regular use. Abstinence not 
reported. 
Placebo-
controlled, double-
blind, crossover 
study with four 
treatment 
conditions. 
Randomised 
treatment order 
using Latin 
Squares. One 
participant 
withdrew. 
Smoked THC 
0.025mg  + 
CBD 0.150 
mg/kg; smoked 
THC 0.025mg; 
smoked 
Placebo   
Blood pressure, 
CMI, DAF, heart 
rate mental 
coordination (peg-
board), modified 
pursuit meter, 
wobble board. 
Combined CBD + THC 
reduced the subjective feeling 
‘high’ associated with THC 
alone   
CBD did not alter the effects of 
THC standing steadiness, hand-
eye coordination, manual 
coordination, heart rate, and 
performance on a delayed 
auditory feedback task = 
Low 
Dalton et al. 
(1976), 
United 
States  
To evaluate the 
interaction between 
THC and CBD in 
doses typical of doses 
being used by 
cannabis smokers. 
Eight healthy volunteers 
(men) 21-24 years, with 
self-reported cannabis use 
at least once, but never 
regular use. Abstinence not 
reported. 
Placebo-
controlled, double-
blind, crossover 
study with two 
treatment 
conditions. 
Randomised using 
Latin Squares 
design. 
Pre-treatment 
(T-30mins) oral 
CBD 
0.150mg/kg 
followed by 
smoked THC 
0.025 mg/kg; 
smoked THC 
0.025 mg/kg; 
CMI, blood pressure, 
heart rate. 
Pre-treatment with CBD did not 
alter the effects of THC on any 
measure = 
Low 
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smoked 
Placebo 
Englund et 
al. (2013)b,  
United 
Kingdom 
To investigate whether 
pre-treatment with 
CBD would attenuate 
positive psychotic 
symptoms and 
cognitive impairment 
following THC. 
48 healthy volunteers 
(21 women; 27 men) 21-50 
years, with self-reported 
cannabis use at least once; 
mean lifetime cannabis use: 
119-137 times. Failure of 
cannulation prevented the 
administration of THC in 
three participants. A urine 
drug screen was carried out. 
No alcohol 24hrs or drugs 
one week before testing. 
Placebo-
controlled, double-
blind, parallel 
study across two 
treatment 
conditions. 26 
received placebo 
and 22 CBD. 
Randomly 
allocated, 
counterbalanced. 
Pre-treatment 
(T-210 mins) 
oral CBD 600 
mg followed by 
intravenous 
THC 1.5 mg; 
pre-treatment 
(T-210 mins) 
oral Placebo 
followed by 
intravenous 
THC 1.5 mg 
Digit span forward 
and backward, 
HVLT-R, MCCB, 
NAB mazes PANSS, 
plasma blood 
concentration, SSPS, 
symbol coding, 
UMACL. 
Clinically significant increase 
in positive symptoms following 
THC were more common in the 
group pre-treated with placebo 
compared with the group pre-
treated with CBD  
Post-THC paranoia was lower 
in the CBD group  
CBD inhibited the effects of 
THC on episodic memory  
No difference in plasma 
concentrations between groups 
= 
Low 
Guy and 
Robson 
(2003), 
United 
Kingdom 
To assess the 
pharmacokinetic 
profile, safety and 
tolerability of the test 
treatments. 
24 healthy volunteers (men) 
18-50 years, with self-
reported cannabis use at 
least once. A urine drug 
screen was carried out pre-
dose, follow-up drug 
screens. No cannabis 30 
days before testing; no 
alcohol or caffeine 48hr 
before testing. 
Placebo-
controlled, double-
blind, crossover 
study across three 
treatment 
conditions. 
Randomised to 
treatment order 
using a Williams 
Square Design. 
Oromucosal 
spray THC 10 
mg + CBD 
10mg; 
oromucosal 
spray THC 10 
mg; oromucosal 
spray Placebo  
  
Blood samples, 
clinical chemistry, 
ECG recordings, 
palatability, self-
rating of subjective 
intoxicating effects, 
urinalysis. 
 
Active treatments intoxication 
scores were low, and effects not 
related to plasma 
concentrations 
THC Tmax statistically 
significantly later following 
CBD+THC than THC alone  
It is possible that the presence 
of CBD in the CBD+THC 
formulation delays the 
absorption of THC  
Wide inter- and intra-subject 
variability 
Low 
  
 
 
 
1
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Haney et al. 
(2016), 
United 
States 
To assess the 
influence of oral CBD 
on the reinforcing, 
subjective, cognitive, 
and physiological 
effects of smoked 
THC. 
31heathy volunteers (14 
women; 
17 men) 18-50 years, with 
self-reported current 
cannabis use; an additional 
19 participants withdrew or 
were excluded. Urine drug 
screen, breathalyser and 
carbon monoxide test. No 
cannabis, alcohol, cannabis 
or tobacco 12hr before 
testing. 
 
Placebo-controlled 
double-blind, 
crossover study 
across eight 
treatment 
conditions. 
Randomised to 
treatment order. 
Pre-treatment 
(T-90mins) oral 
CBD 200, 400, 
800 mg 
followed by 
smoked THC 
42 mg; pre-
treatment (T-
90mins) oral 
Placebo 
followed by 
smoked THC 
42 mg 
Blood pressure, 
CPT, heart rate, 
DSST, self-rating of 
mood and subjective 
intoxicating effects. 
CBD did not significantly alter 
the increase subjective 
intoxication effects or increased 
estimates of the street value of 
the cannabis smoked associated 
with THC alone =  
CBD did not significantly 
influence the significant 
increase in peak heart rate 
following THC = 
Low 
Hindocha et 
al. (2015); 
Morgan et 
al. (2018); 
Wall et al. 
(2019) 
United 
Kingdom 
To determine the 
effects of THC and 
CBD, both alone and 
in combination on 
emotional facial affect 
recognition subjective 
effects and memory 
function. Secondary 
analyses: To 
investigate psychosis-
like effects. 
48 heathy volunteers (14 
women; 34 men) 18-26 
years, with either daily (24) 
or recreational (24) self-
reported cannabis use. No 
alcohol or illicit drug use 
24hr before testing.   
 
Placebo-
controlled, double-
blind, 
crossover study 
across four 
treatment 
conditions. 
Analysed by four 
groups: high vs 
low SPQ score; 
and frequency of 
cannabis use: daily 
vs recreational. 
Randomised using 
a Latin squares 
design. 
Vaporised THC 
8 mg + CBD 16 
mg; vaporised  
THC 8 mg; 
vaporised 
Placebo 
 
BSS, dot-probe task, 
emotional 
processing task, 
genotyping, MCQ, 
N-back, prose recall, 
self-rating of 
subjective 
intoxicating effects, 
trail making task. 
 
Primary outcomes: CBD 
reduced the impairment of 
recognition of ambiguous faces 
of 40% intensity associated 
with THC  
THC alone and combined 
THC+CBD equally increased 
feelings of being ‘stoned’ = 
Secondary outcomes: Both 
THC alone and in combination 
with CBD increased negative 
symptoms on the BPRS, 
perceptual distortions & 
cognitive disorganisation on the 
PSI = 
The influence of CBD on THC 
may differ according to 
variation in endocannabinoid 
system genetics. 
Low 
  
 
 
 
1
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Hollister 
and 
Gillespie 
(1975), 
United 
States  
To test if CBD and 
CDN interact with the 
effects of THC. 
15 healthy volunteers (men) 
18+ years, with self-
reported cannabis use at 
least once. Abstinence not 
reported. 
Crossover study 
across three 
treatment 
conditions. 
Randomised using 
Latin Squares 
design. 
Oral THC 20 
mg + CBD 40 
mg; oral THC 
20 mg; oral 
Placebo 
ARCI, conjunctival 
hyperaemia, drug 
intensity rating, 
pulse rate, self-rating 
of subjective 
intoxicating effects, 
urinalysis. 
 
The onset of effects measured 
by a narrative summary of 
subjective effects of THC+ 
CBD compared to THC alone 
was slightly slower  
Pulse rate changes were similar 
across treatments = 
Metabolites in urine samples 
were more numerous following 
the THC + CBD combination 
than after THC alone  
Some 
concerns 
Hunt et al. 
(1981),  
United 
States 
To investigate the 
effect of CBD on THC 
pharmacokinetics. 
Four healthy volunteers 
(men) 22-30 years, with 
self-reported cannabis use 
4-10 times; and cigarettes 
per week for an average of 
8.3 years before the study. 
Participants remained on-
site to ensure abstinence 
from drugs and medication 
48hrs before testing. 
Placebo-
controlled, double-
blind, crossover 
study across two 
treatment 
conditions. 
Participants 
counterbalanced to 
receive treatments 
in a different order. 
Pre-treatment 
(T-480, -300, -
120 mins) oral 
CBD 500 mg 
followed by 
intravenous 
THC 2 mg; pre-
treatment (T-
480, -300, -120 
mins) oral 
Placebo 
followed by 
intravenous 
THC 2 mg 
Blood sample, 
fingertip 
temperature, heart 
rate 
pharmacokinetics, 
self-rating of 
subjective 
intoxicating effects, 
urinalysis. 
 
Pre-treatment with CBD did not 
alter the pharmacokinetic or 
pharmacodynamic effects of 
THC = 
There may be minimal effect on 
the formation and excretion of 
metabolites. Total (metabolic) 
blood clearance of THC 
17ml/min/kg without CBD and 
20.9ml/min/kg with CBD  
Some 
concerns  
Karniol et 
al. (1974)c, 
Brazil 
To investigate whether 
THC + CBD would 
induce less 'high' or 
psychosis-like effects 
that would be 
expected from THC 
alone. 
50 recruited (10 excluded 
before assignment to a 
group) healthy volunteers 
(men), 21-34 years, 22 with 
self-reported cannabis use 
at least once; 18 had never 
used cannabis. No alcohol 
24hr before testing. 
Placebo-
controlled, double-
blind, parallel 
study across eight 
treatment 
conditions. Groups 
balanced for age 
and weight. 
Oral THC 30 + 
CBD 15, 30 or 
60 mg; oral 
THC 30 mg; 
oral Placebo  
 
 
Pulse rate, self-
rating of subjective 
intoxicating effects, 
time production task.  
 
CBD seemed to block the 
anxiety-provoking effects of 
THC  
CBD was found to attenuate 
several effects of THC, such as 
pulse rate acceleration, time 
production impairment and 
psychological disturbances  
Some 
concerns 
  
 
 
 
2
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T. P. 
Freeman, 
Pope, et al. 
(2018); 
Lawn et al. 
(2016); 
Wall et al. 
(2019),  
United 
Kingdom  
To examine acute 
effects of THC + CBD 
and THC alone on 
effort-related decision-
making. Secondary 
aims: Investigate 
response to music in 
brain regions sensitive 
to reward and 
emotion, and 
subjective ratings 
following THC and 
test if offset by CBD. 
17 healthy volunteers (nine 
women; eight men) 18-70 
years, with self-reported 
cannabis use (≥4 times in 
the last year, ≤3 
times/week; one participant 
excluded in T.P. Freeman et 
al. 2018. Urine drug screen 
at each session, no alcohol 
or illicit drugs 24hr before 
each testing session. 
Placebo-
controlled, double-
blind, crossover 
study across four 
treatment 
conditions. 
Randomised to 
treatment order 
using a Latin 
squares design. 
Vaporised THC 
8 mg + CBD 10 
mg;  vaporised  
THC 8 mg; 
vaporised 
Placebo 
 
Blood pressure, 
EEfRT, fMRI, heart 
rate, SDS Snaith 
Hamilton pleasure 
scale, self-rating of 
subjective 
intoxicating effects, 
temporal 
experiences of 
pleasure scale. 
Primary outcomes: CBD did 
not affect reduced motivation 
for high-effort choice 
associated with THC to make a 
to earn rewards = 
CBD altered increased 
sensitivity to monetary value 
following THC  
Secondary outcomes: Higher 
enhanced sound perception 
after THC+CBD than THC  
THC alone dampened the 
response to music in several 
reward and emotion brain 
regions, THC+CBD did not 
differ from placebo and showed 
greater connectivity  
THC alone reduced 
connectivity within the salience 
network when compared to 
THC + CBD  
Low 
Juckel et al. 
(2007); 
Nadulski et 
al. (2005); 
Roser et al. 
(2009); 
Roser et al. 
(2008); 
(Stadelmann 
et al., 
2011)d, 
Germany  
To investigate the 
effects of CBD on the 
pharmacokinetics of 
THC. Secondary 
analyses: investigate 
psychotic states and 
schizophrenic 
conditions; acute 
effects of 
cannabinoids on P300 
amplitude; 
psychomotor 
performance by using 
28 healthy volunteers 
recruited a, 20-24 included 
depending on the analysis 
(up to 12 women; 12 men). 
Three participants had a 
panic attack. For others 
there were technical issues 
with ERP recording or 
quality of recording. 
Participants were 18-45 
years with self-reported 
cannabis use at least once, 
but never regular use. Urine 
Placebo-
controlled, double-
blind, crossover 
study across three 
treatment 
conditions.  
Randomised to 
treatment order.  
Oral THC 10 
mg + CBD 5.4 
mg; oral THC 
10 mg; oral 
Placebo 
AIR-scales, auditory 
evoked MMN 
recorded via ERP 
recording, blood 
plasma levels, DNA 
genotyping, eye-
movement finger 
tapping asymmetry, 
inter-manual 
coordination. 
 
Primary outcomes: CBD 
inhibits the metabolic 
hydroxylation of THC; but the 
effect is small  
Secondary outcomes: Greater 
auditory evoked MMN 
amplitude following 
THC+CBD but not THC alone 
 
No difference in P300 
amplitudes under THC and 
THC+CBD =  
Some 
concerns 
  
 
 
 
2
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a finger tapping test 
series; if (AAT)n 
polymorphism 
differentially 
modulates 
cannabinoid effect on 
P300 generation 
during an auditory 
choice reaction task. 
screen for illicit drugs 
before each testing session, 
self-report no cannabis one 
month; no alcohol, caffeine, 
48hrs before; no nicotine 
12hrs. 
THC+CBD but not THC alone 
reduced right-hand tapping 
frequencies   
>10/>10 genotypes showed a 
decrease of P300 amplitude and 
prolongation of P300 latency 
under THC alone but not 
THC+CBD   
Correlation between AAT 
repeats and P300 variables for 
THC alone. 
Nicholson 
et al. 
(2004), 
United 
Kingdom 
To assess the effects 
of cannabis extracts on 
nocturnal sleep, early 
morning performance, 
memory, and 
sleepiness. 
Eight healthy volunteers 
(four women; four men) 18-
35 years, with self-reported 
cannabis use at least once, 
but never regular use. No 
cannabis for a month; no 
alcohol 48hrs. 
Placebo-
controlled, double-
blind, crossover 
study across four 
treatment 
conditions. 
Randomisation not 
indicated. 
Oromucosal 
spray THC 15 
mg + CBD 15 
mg; oromucosal 
spray THC 15 
mg; oromucosal 
spray Placebo 
Blood plasma levels, 
choice reaction time, 
delayed and 
immediate word 
recall, digit symbol, 
heart rate, letter and 
digit memory recall, 
multi-attribute task 
battery, pulse rate, 
self-rating of 
subjective 
intoxicating effects, 
sleepiness, sustained 
attention, sleep 
latency. 
THC alone and in combination 
with CBD increased sleepiness 
30minutes after waking, 
negatively affected mood = 
THC+CBD but not THC alone 
decreased stage 3 sleep and 
increased time spent awake  
THC decreased latencies to 
early morning sleep and 
impaired episodic memory, not 
present with THC + CBD  
Low 
Zuardi et al. 
(1982), 
Brazil  
To investigate whether 
CBD diminished the 
anxiety produced by 
THC in healthy 
volunteers, and to 
verify whether this 
effect occurs through a 
 Eight healthy volunteers 
(two women; six men) 20-
38 years, with self-reported 
cannabis use at least once, 
three had never used 
cannabis. 15 days 
Placebo-
controlled, double-
blind, crossover 
across six 
treatment 
conditions. 
Participants 
Oral THC 0.5 
mg/kg + CBD 1 
mg/kg; oral 
THC 0.5 
mg/kg; oral 
Placebo 
 
ARCI-Ma, 
interviews of 
subjective effects, 
pulse rate, Scale of 
Bodily Symptoms, 
self-rating of 
subjective 
THC increased pulse rate, CBD 
did not alter this effect = 
When combined with CBD 
blocks the anxiety provoked by 
THC   
CBD blocks subjective effects 
measured on the ARCI-Ma  
Some 
concerns  
  
 
 
 
2
2
 
general block of the 
action of THC or a 
specific effect on the 
anxiety. 
abstinence of cannabis 
before testing. 
received 
treatments in a 
different order. 
intoxicating effects; 
STAI; self-rating of 
subjective 
intoxicating effects. 
Notes. effect:  increases effects of THC;  decreases effects of THC, = no difference of effect; *interventions – only interventions relevant to the review are reported; 
Risk of bias tool: Cochrane’s risk of bias tool (either for parallel/crossover study design); Where multiple publications for single study first publication reported as 
primary outcomes, all subsequent as secondary outcomes. AIR-scale: visual Analogue Intoxication Rating Scales; ARCI-Ma: Addiction Research Center Inventory for 
Marihuana Effects; BSS: Bodily Symptoms Scale; CBD: cannabinol; CMI: Cornell Medical Index; CPT Continuous Performance Task; DAF: Delayed Auditory 
Feedback; DAT: Divided attention task; DSST: Digit Symbol Substitution Task; DSST: Digit Symbol Substitution Task; ECG: electrocardiogram; EEfRT: Effort 
expenditure for rewards task; ERP: event-related brain potential; fMRI: functional magnetic resonance imaging; hr: hours; HVLT-R: Hopkins Verbal Learning Task-
Revised; iv: intravenous; MCCB: MATRICS Consensus Cognitive Battery; MCQ: Marijuana Craving Questionnaire; MMN: mismatch negativity; n: total number of 
participants; NAB: Neuropsychological Assessment Battery; PANSS: Positive and Negative Syndrome Scale; PASAT: Paced Auditory Serial Addition Task; SDS: 
Severity of Dependence Scale;; SPSS The State Social Paranoia Scale, STAI: Spielberger's State-Trait Anxiety Inventory; THC: delta-9-tetrahydrocannabinol; UMACL: 
University of Wales Mood Adjective Checklist; VDA: Vienna Determination Apparatus; a. 166 divided into 16 groups; b. placebo n= 22 CBD n=26, c. 8 groups of 5; 
d.  not all participants completed all measures in this study 2 men, and 2 women did not complete ERP recording due to technical issues and three women had a panic 
attack. Therefore Roser et al. (2008) and Stadlemann et al. (2011) included 20 participants; Nadulski et al. (2005) and Roser et al. (2009) included 24 participants; 
Juckel et al. (2007) included 22 participants. Underlined study is first publication of the study.  
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3.2. Participants  
All studies included healthy volunteers, and all except two (Karniol et al., 1974; Zuardi 
et al., 1982) included only participants with previous experience of cannabis use.  
3.3. Treatment characteristics 
Table 1 shows the treatment characteristics of each study. There was considerable 
variability in the doses of both THC and CBD, and in the ratio of THC to CBD. There 
was also heterogeneity in the route of administration used across treatments and 
studies. For CBD administration, eight studies used oral doses (5.4mg-800mg), one 
intravenous (5mg), two vaporised (4mg-16mg), two smoked (0.150-0.320mg/kg), and 
two used an oromucosal spray (10mg-15mg). For THC administration, six studies used 
oral (10mg-40mg), three intravenous (1.25mg-2mg), three smoked (42mg or 0.215-
0.025mg/kg), two vaporised (8mg), and two used an oromucosal spray (10mg-15mg). 
Five studies used a design where a dose of CBD or placebo was administered as a pre-
treatment before THC administration. These were administered either orally (200-
1500mg) 480 to 90 minutes before, via a smoked joint (0.150mg/kg), 30 minutes 
ahead, or intravenously immediately before THC. Where studies used a design that 
included a pre-treatment, they did not include a pure placebo condition and used 
baseline measurements which were administered before any drug. The remaining 
studies all used a design which included a treatment condition where participants 
received placebo only. 
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3.4. Risk of bias within studies 
Only ten studies were found to be at low risk of bias (Arkell et al., 2019; Bhattacharyya 
et al., 2010; Dalton et al., 1976; Englund et al., 2013; Guy & Robson, 2003; Haney et 
al., 2016; Hindocha et al., 2015; Lawn et al., 2016; Nicholson et al., 2004); some 
concerns were found for six studies (Bird et al., 1980; Hollister & Gillespie, 1975; 
Hunt et al., 1981; Karniol et al., 1974; Nadulski et al., 2005; Zuardi et al., 1982); none 
were evaluated as high risk of bias. A table summarising the findings from the risk of 
bias assessment can be found in Appendix G.  
3.5. Risk of bias across studies  
Indicators for risk of bias across studies were assessed (Boutron et al., 2019). Overall 
this area of research has low risk of publication bias as many studies report a mixture 
of significant and non-significant findings. This review only included studies 
published in the English language and therefore may have missed important findings 
reported in different languages. Some studies were funded by an industry sponsor and 
therefore present a potential conflict of interest (Guy & Robson, 2003; Nicholson et 
al., 2004). One possible bias across studies is recreational use of cannabis external to 
the study, which may have resulted in residual drug effects, and could have affected 
participants’ performance. Another bias across studies may have been that individuals 
were able to identify the placebo condition over active treatment conditions, although 
this would not be expected to be a concern for the comparison between the THC versus 
THC+CBD conditions.  
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3.6. Synthesis of results  
Table 1 summarises the findings of comparisons between THC with and without CBD 
for the studies included in this review. A narrative synthesis of the findings from the 
review was conducted because the heterogeneity of outcomes used across studies 
precluded meta-analysis. 
3.6.1. Pharmacokinetic effects 
Pharmacokinetics were assessed in eight studies. Overall, typically studies reported 
that CBD did not significantly alter the pharmacokinetic profile of THC. Although 
three studies suggested that CBD may have a small effect on the metabolism of THC, 
findings were inconsistent. Three out of the eight studies were rated as having some 
concerns in at least one domain of the risk of bias assessment (Hollister & Gillespie, 
1975; Hunt et al., 1981; Nadulski et al., 2005). 
In a study of 14 participants, the combination of vaporised THC (13.75mg) and 
vaporised CBD (13.75mg) was associated with significantly increased peak plasma 
concentrations of THC when compared to vaporised THC (13.75mg) alone (Arkell et 
al., 2019). Although not statistically significant, the area under the curve (0-3 hours) 
for plasma THC was higher for the combined THC+CBD treatment than THC alone. 
Nadulski et al. (2005) showed that co-administration of oral CBD (5.4mg) altered the 
metabolism of oral THC (10mg) by partially inhibiting the cytochrome P450 enzymes, 
which hydroxylate THC to its metabolite 11-hydroxy-THC. The authors suggest this 
may lead to a slight rise and earlier peak in THC concentration when THC is combined 
with CBD. However, in this study of 24 participants there was wide inter-participant 
variability. In a later publication of the same study, Roser et al. (2009) report 
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significantly higher levels of 11-OH-THC and THC-COOH in women compared to 
men following THC with CBD, but not following THC alone. In a study of 24 
participants, Guy and Robson (2003) found the time taken to reach the maximum 
plasma concentration for THC was significantly later following oromucosal spray of 
THC (10mg) and CBD (10mg) combined when compared to oromucosal spray of THC 
(10mg) alone. The authors concluded that CBD might delay the absorption of THC. 
However, this study also reported wide inter- and intra-participant variability in 
pharmacokinetic parameters. There were no other significant differences in the 
pharmacokinetic profiles between the two test treatments. 
In a study of only four participants, Hunt et al. (1981) concluded that pre-treatment 
with three doses of oral CBD at eight, six and two hours (total dose 1500mg) before 
intravenous THC (2mg) had no significant effect on the pharmacokinetics of THC 
when compared to pre-treatment with placebo. The authors report, however, that there 
may be a “real but slight” effect of CBD on the metabolism of THC, where total 
(metabolic) blood clearance of THC averaged 17ml/min/kg without CBD and 
20.9ml/min/kg with CBD. In a study of 15 participants, Hollister and Gillespie (1975) 
found that compared to oral THC (20mg) administered alone, when combined with 
oral CBD (40mg) THC was associated with increased concentrations of THC 
metabolites in urine. However, they attributed this to the additional presence of CBD 
rather than a change in the metabolism of THC. 
 
A small crossover study (n=6) found that pre-treatment with intravenous CBD 
(5mg) did not influence blood levels (area under the curve from 0 to 120 minutes) of 
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THC following intravenous THC (1.25mg) when compared to placebo (Bhattacharyya 
et al., 2010). Similarly, a parallel group study (n=36) found no significant difference 
in plasma concentration of THC following pre-treatment with oral CBD (600mg) or 
placebo (Englund et al., 2013). Nicholson et al. (2004) reported plasma concentrations 
for THC, OH-THC and COOH-THC but did not report comparisons between the 
treatment groups.  
3.6.2. Pharmacodynamic effects 
3.6.2.1. Pulse rate 
Of the ten studies that reported outcomes for the effects of cannabinoids on pulse rate, 
the risk of bias assessment found some methodological concerns for four studies (Bird 
et al., 1980; Hollister & Gillespie, 1975; Karniol et al., 1974; Zuardi et al., 1982). Eight 
studies found that both THC alone and the combination of THC and CBD increased 
pulse rate when compared to baseline measurements or placebo, but there was no 
significant difference between the THC alone and the combination of the two drugs 
(Bird et al., 1980; Dalton et al., 1976; T. P. Freeman, Pope, et al., 2018; Guy & Robson, 
2003; Haney et al., 2016; Hollister & Gillespie, 1975; Zuardi et al., 1982). Another 
study, which investigated the effect of THC and CBD on sleep in just eight 
participants, found no differences in pulse rate between treatments (sublingual drops 
of a placebo, THC 10mg, THC 10mg + CBD 10mg) during the 30 minutes following 
drug administration (Nicholson et al., 2004). However, on waking the next morning 
both the THC alone and in combination with CBD were associated with postural 
systolic hypotension, with compensatory increases in supine and erect pulse rate when 
compared to placebo. 
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In contrast, Karniol et al. (1974) reported results from a very small parallel 
group study (n=40; n=5 per group) where oral THC (30mg) alone significantly 
increased pulse rate, but when THC was combined with low dose oral CBD (15mg), 
it seemed to increase pulse rate further. However, when THC (30mg) was combined 
with higher doses of oral CBD (30mg or 60mg), the combination seemed to have the 
opposite effect, reducing the acceleration of pulse rate associated with THC alone.  
3.6.2.2. Blood pressure  
Three studies reported outcomes for blood pressure. There were no concerns about the 
risk of bias.  Findings of two studies suggest that CBD might alter the effect of THC 
on blood pressure. Guy and Robson (2003) reported no notable changes in diastolic 
blood pressure, however, three hours after drug administration the mean systolic blood 
pressure decreased by 10.3 mmHg following THC (10mg) alone; by 4.4 mmHg 
following sublingual THC (10mg) and CBD (10mg) condition; and 5.1 mmHg during 
the placebo period. In a crossover study of 17 participants, T. P. Freeman, Pope, et al. 
(2018) reported increased systolic blood pressure following both THC (8mg) alone 
and the combination of THC (8mg) and CBD (10mg) when compared to placebo, 
whereas diastolic blood pressure increased after drug administration in the THC alone 
condition, but not following co-administration of THC and CBD. However, Haney et 
al. (2016) did not find significant differences in blood pressure across their different 
treatment groups (n=31) in a study of pre-treatment (90mins) with either oral CBD 
(200, 400, 800 mg) or placebo 90 minutes before smoking a joint of THC (~42 mg).  
3.6.3. Subjective intoxicating effects  
There was much variation in the way studies measured subjective effects. Of the nine 
studies, most included visual analogue scales (VAS) where participants self-rated 
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feelings of intoxication. Two studies presented some concern about the potential risk 
of bias (Bird et al., 1980; Zuardi et al., 1982). The evidence for CBD potentially 
reducing the acute subjective effects of THC comes from two small experimental 
studies. In Dalton et al.’s (1976) double-blind, crossover study (n=15), smoked THC 
(0.025mg/kg) alone was associated with an increase in feeling “high” and increased 
drug-related effects on a modified version of the Cornell Medical Index (CMI) 
symptoms (a list of symptoms self-rated for intensity on a 0 to 4 scale). CBD 
(0.150mg/kg) significantly reduced the effects of THC. Similarly, Zuardi et al. (1982) 
found in a small double-blind crossover study (n=8), that oral THC (0.5mg/kg) and 
CBD (1mg/kg) combined reduced the increase in subjective feelings on the Addiction 
Research Center Inventory for marihuana effects (ARCI-Ma) associated with oral 
THC (0.5mg/kg) alone. In contrast to these findings, seven studies found no evidence 
for CBD moderating the subjective intoxicating effects of THC (Arkell et al., 2019; 
Bird et al., 1980; Dalton et al., 1976; T. P. Freeman, Pope, et al., 2018; Haney et al., 
2016; Hindocha et al., 2015; Roser et al., 2009).  
3.6.4. Anxiety  
Three studies, two of which have an unclear risk of bias (Karniol et al., 1974; Zuardi 
et al., 1982), reported outcomes for anxiety-related symptoms. The interaction of CBD 
on the anxiety-inducing effects of THC was first described by (Karniol et al., 1974) in 
a placebo-controlled, double-blind, parallel group study (n=40; n=5 per group). The 
study used a specially developed scale (Appendix H) where subjective drug effects 
were graded (from 0 to 4) if the participant reported at least three symptoms listed in 
each grade (Karniol & Carlini, 1973). The scale lists anxiety and psychosis-related 
items, for example, Grade 0 "nothing or slight anxiety", to Grade 4, "panic; intense 
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sensation of being watched; impossibility to have coherent thoughts due to the rapid 
flow of ideas”. Oral THC (30mg) induced Grade 4 effects in four out of five 
participants. However, when oral CBD (15mg, 30mg & 60mg respectively) was 
combined with oral THC (30mg), 3 participants out of 15 experienced these effects. A 
dose-dependent effect was suggested, where no participants in the high CBD group 
met criteria for Grade 4. Zuardi et al.’s (1982) double-blind, crossover study (n=8) 
found that when oral CBD (1mg/kg) was administered together with oral THC 
(0.5mg/kg), it attenuated the significant increase in anxiety symptoms on the State-
Trait Anxiety Inventory (STAI; Spielberger, 2010) associated with oral THC 
(0.5mg/kg) alone. Arkell et al. (2019) reported in a study of 14 participants that 
vaporised THC (13.75 mg) both with and without vaporised CBD (13.75 mg) produced 
small but significant increases in ratings of anxiety and increases on the STAI 15 
minutes after the drug was administered.  However, only after vaporised THC (13.75 
mg) alone were these ratings still increased after an hour.   
3.6.5. Psychotomimetic and psychosis-like experiences  
Three studies included in this review investigated psychotomimetic and psychosis-like 
effects following the acute administration of THC. There were no concerns about 
potential bias. THC induced acute psychosis-like effects on the Positive and Negative 
Syndrome Scale (PANSS; Kay, Fiszbein, & Opler, 1987), following intravenous THC 
(1.25mg) in three out of six participants (Bhattacharyya et al. 2010). This double-blind, 
pseudo-randomised, crossover study, found that pre-treatment with intravenous CBD 
(5mg), when compared to placebo, ameliorated the psychotomimetic effects of THC. 
Comparable effects were seen in Englund et al.’s (2013) randomised, double-blind, 
parallel study (n=48), which showed that although there was no statistical difference 
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in the mean increase in scores on the PANSS after intravenous THC (1.5mg) following 
pre-treatment of placebo or oral CBD (600mg), fewer participants treated with CBD 
showed a clinically significant increase in positive symptoms (≥3 points). Paranoia 
rated on the State Social Paranoia Scale (SSPS; D. Freeman et al., 2007) was lower in 
the group of participants who received pre-treatment with CBD when compared to 
those who received pre-treatment with placebo (Englund et al., 2013).  
In contrast to these findings, however, Morgan et al. (2018) did not find any 
difference in acute psychotomimetic effects between two treatment conditions of 
vaporised THC (8mg) with or without vaporised CBD (16mg) respectively. The 
double-blind, placebo-controlled, crossover study (n=48), showed that THC both 
alone and THC combined with CBD increased negative symptoms on the Brief 
Psychotic Rating Scale (BPRS; Overall & Gorham, 1962) and total scores on the 
Psychotomimetic States Inventory (PSI; Mason, Morgan, Stefanovic, & Curran, 
2008). In particular scores on the perceptual and cognitive distortion subscales of the 
PSI were significantly higher than scores on placebo. The study did not find any 
differences in these effects based on frequency of cannabis use or trait schizotypal 
symptoms.  
3.6.6. Cognitive effects 
Seven studies reported outcomes related to cognitive tasks including those focused on 
memory, auditory processing, emotion and reward. Two studies presented some 
concerns on the risk of bias assessment (Juckel et al., 2007; Karniol et al., 1974; Roser 
et al., 2008; Stadelmann et al., 2011). 
  32 
3.6.6.1. Episodic memory 
As previous studies have shown, THC alone had an acute detrimental effect on 
episodic memory in five studies (Dalton et al., 1976; Englund et al., 2013; Karniol et 
al., 1974; Morgan et al., 2018; Roser et al., 2008). Whether CBD is protective against 
these effects was less clear. Englund et al.’s (2013) study (n=48) showed that 
intravenous THC (1.5mg) alone impaired episodic memory on both the immediate and 
delayed recall tasks from the Hopkins Verbal Learning Task-Revised (HVLT-R; 
Brandt & Benedict, 2001) when compared to baseline. Participants allocated to pre-
treatment with oral CBD (600mg) resulted in the same level of immediate recall 
following THC, but the impairment for delayed recall was ameliorated following CBD 
pre-treatment. In a cross over study (n=48) Morgan et al. (2018) found that vaporised 
THC (8mg) both alone and when combined with vaporised CBD (16mg) showed the 
same level of impairment in episodic memory on prose recall in the story recall task 
from the Rivermead Behavioural Memory Test (RBMT; Wilson, Cockburn, Baddeley, 
& Hiorns, 1989), when compared to placebo.  
3.6.6.2. Attention and working memory 
Morgan et al. (2018) found that vaporised THC (8mg) both alone and when combined 
with vaporised CBD (16mg) impaired working memory on the N-back task (Kirchner, 
1958). Karniol et al. (1974) showed that CBD reduced impairments on a time 
production task, which taps working memory processes (Lewis & Miall, 2006). 
Participants were instructed to estimate 60-second time intervals, and the study (n=40; 
n=5 per group) demonstrated a phenomenon where administration of oral THC (30mg) 
alone led to an acceleration of the 'internal clock,' which was not present when oral 
THC (30mg) was co-administered with oral CBD (15mg, 30mg or 60mg). However, 
a parallel group study (n=48) by Englund et al. (2013) found that pre-treatment with 
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oral CBD (600mg) did not seem to alter the impairing effects of intravenous THC 
(1.5mg) on working memory tasks, including digit span forward and backwards. 
Arkell et al. (2019) found that vaporised THC (13.75mg) alone, but not THC combined 
with vaporised CBD (13.75mg), induced impairments after 20 minutes on the Digit 
Symbol Substitution Test (McLeod, Griffiths, Bigelow, & Yingling, 1982) compared 
to placebo in 14 participants. However, on the Divided Attention Task (Kleykamp, 
Griffiths, & Mintzer, 2010) participants showed impaired performance 20 minutes 
following THC combined with CBD compared to THC alone or placebo.    
3.6.6.3. Semantic memory  
In a crossover study which included 48 participants, Morgan et al. (2018) found that 
verbal fluency was enhanced when vaporised THC (8mg) was combined with CBD 
(16mg), but there was no difference in verbal fluency performance between vaporised 
THC (8mg) alone and placebo. 
3.6.6.4. Auditory processing 
Juckel et al. (2007) aimed to investigate a component of auditory evoked brain 
potential (ERP) called mismatch negativity (MMN) amplitude which is an automatic, 
and pre-attentive event-related potential component associated with auditory 
processing and working memory. MMN processing is impaired in people who have a 
diagnosis of schizophrenia (Javitt, Doneshka, Grochowski, & Ritter, 1995). The 
analysis (n=22) showed that the combination of oral THC (10mg) and oral CBD 
(5.4mg), but not oral THC (10mg) alone, was associated with higher amplitudes at the 
central electrode compared to placebo. No deficits were found in the THC alone 
condition. The authors suggest the improvement in performance may occur due to the 
improved processing due to the effect of CBD on auditory information processing. In 
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the same study Roser et al. (2008) analysed the amplitudes of auditory evoked P300 
in the same sample, to investigate the effect of THC alone and in combination with 
CBD on electroencephalography (EEG) correlates of working memory and attentional 
functioning during a choice reaction time task. The analysis (n=20) showed that THC 
alone, and when administered with CBD, significantly reduced P300 amplitude at 
midline frontal, central and partial electrodes and therefore CBD did not prevent the 
acute impairment of THC alone.  
Stadelmann et al. (2011) later investigated whether the (AAT)n polymorphism 
differentially modulates the effects of THC alone and THC combined with CBD on 
P300 generation during an auditory choice reaction task in the same sample (n=20). 
There was a significant decrease of P300 amplitude and prolongation of P300 latency 
for both >10 genotypes in the THC alone condition, but not in the condition where 
THC and CBD were combined. There was a significant correlation between the 
number of AAT repeats and P300 variables for the THC condition. The authors suggest 
that this finding seems to indicate that the CNR1 gene may differentially alter 
sensitivity to the acute effects of cannabinoids on P300 generation. 
Dalton et al. (1976) reported that smoked THC (0.025mg/kg) decreased the 
frequency of verbal responses and increased errors on delayed auditory feedback 
(DAF) both alone and in combination with smoked CBD (0.150 mg/kg) in 16 
participants. In a randomised, double-blind, crossover study (n=14) participants 
showed transient impairments following vaporised cannabis containing THC 
(13.75mg) both with and without CBD (13.75mg) on the Paced Auditory Serial 
Addition Task (Herrmann et al., 2015) when compared to placebo (Arkell et al., 2019).  
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3.6.7. Emotion and reward processing  
Two studies investigated the differential effects of THC and CBD during emotion and 
reward processing tasks. These studies presented a low risk of bias. Hindocha et al. 
(2015) demonstrated impairments in emotional processing on a task which assessed 
participants’ emotional facial affect recognition (happy, sad, fearful, angry, disgust 
and surprise) following vaporised THC alone (8mg). The study (n=48) found that the 
impairment induced by vaporised THC (8mg) in emotional processing was blocked 
when it was combined with vaporised CBD (16mg).  
In a similar study, Lawn et al. (2016) investigated the effects of cannabis 
containing different doses of cannabinoids on a task which taps effort-related decision 
making, the effort expenditure for rewards task (Treadway, Buckholtz, Schwartzman, 
Lambert, & Zald, 2009). The study (n=17) demonstrated that vaporised THC (8mg) 
increased sensitivity to probability and magnitude of reward (expected monetary 
value) relative to both placebo, and vaporised THC (8mg) administered with vaporised 
CBD (10mg). In a later publication from the same study (T. P. Freeman, Pope, et al., 
2018), the researchers investigated the effects of cannabinoids while participants 
listened to music during functional magnetic resonance imaging (fMRI). Participants 
reported enhanced sound perception following co-administered THC and CBD when 
compared to THC alone. THC alone dampened the haemodynamic response to music 
in the bilateral auditory cortex, right amygdala, right hippocampus and para-
hippocampal gyrus, and right ventral striatum. However, when THC was combined 
with CBD, this effect was offset, and the response to music in these brain regions did 
not differ from placebo. Additionally, THC with CBD caused greater functional 
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connectivity between the ventral striatum and auditory cortex during musical listening 
when compared to THC alone. 
In the same study, Wall et al. (2019) investigated the effects of THC alone, 
THC in combination with CBD, and placebo during resting state fMRI. THC alone, 
and in combination with CBD, reduced connectivity across the default mode network 
(DMN). The DMN is a network of brain regions which are active in periods of wakeful 
rest and internally focused states and was defined in this study as brain regions 
showing positive connectivity with the posterior cingulate cortex (PCC). THC reduced 
connectivity within the DMN, and this effect correlated with increased subjective 
intoxicating effects (feeling “stoned” and “high”). THC and THC+CBD showed 
spatially dissociable effects on the salience network (SN) (Seeley et al., 2007) which 
toggles between internally focused states and external action and goal directed 
behaviours, defined in this study as brain regions showing positive connectivity with 
the anterior insula. Treatment effects across the whole SN indicated that THC alone 
showed an overall reduction in connectivity within the salience network when 
compared to THC co-administered with CBD.  
3.6.8. Psychomotor performance  
Four studies investigated the effects of cannabinoids on psychomotor performance. 
One study presented some concerns in a risk of bias assessment (Roser et al., 2009). 
Roser et al. (2009) investigated impairments in psychomotor performance which have 
been consistently associated with schizophrenia. In a randomised crossover study  
outcomes are reported on a finger tapping task in 24 healthy volunteers, following 
either oral THC (10mg) with CBD (5.4mg) combined, oral THC (10mg) alone, or oral 
placebo. On each of the three testing days participants completed a task which involved 
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five 15-second, finger tapping ‘sessions’ (right- and left-hand tapping), with two 
sessions involving tapping while completing other tasks (humming or reading) and a 
final session with alternate tapping. The study reported that THC co-administered with 
CBD, led to significantly reduced right-hand tapping frequencies compared to placebo 
in all but the alternate tapping sessions. There were no differences between placebo 
and the THC only condition. However, THC alone impaired left-handed frequencies 
in sessions without distraction tasks (two out of the five sessions); this impairment was 
associated with increased plasma concentrations of 11-OH-THC.  
In a study investigating the effects of cannabinoids on a driving simulation task 
(n=14), both vaporised THC (13.75mg) with and without CBD  (13.75mg) were found 
to increase lane weaving during a car following task (Arkell et al., 2019) when 
compared to placebo. Bird et al. (1980) did not find any evidence for oral CBD 
(0.320mg/kg) moderating the effects of oral THC (0.215mg/kg). This parallel study 
(16 groups, n=116) combined several outcomes to create three factors. Visual, 
auditory, and complex reaction time were combined to create a reaction speed factor 
(factor 1), a standing steadiness factor included scores from eyes open and closed 
standing steadiness tasks (factor 2), and a third factor included the pursuit rotor and a 
psychomotor coordination and the Vienna determination apparatus (VDA) data (factor 
3). THC alone impaired both standing steadiness and psychomotor coordination, but 
CBD did not moderate this effect. Dalton et al. (1976) also found in a crossover study 
(n=16) that both combined smoked THC (0.025mg/kg) and CBD (0.150mg/kg) and 
smoked THC (0.025mg/kg) alone, when compared to placebo, reduced standing 
steadiness using a wobble board, hand-eye coordination on an attentive motor 
performance task, using a modified pursuit meter (Evans et al., 1973) and manual 
coordination and dexterity using a pegs test.   
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3.6.9. Sleep 
One study assessed the acute effects of THC, with and without CBD, on sleep. 
Nicholson et al. (2004) investigated the effect of oromucosal spray containing THC 
(15mg) and CBD (15mg) when compared to oromucosal spray containing THC 
(15mg) alone in eight participants. The study found that THC had sedative qualities, 
however, when THC was combined with CBD the spray increased the duration of 
wakefulness and stage 3 nocturnal sleep suggesting that CBD may have some 
activating properties. There were no differences in participants’ ratings of sleep onset, 
duration or quality between treatments. However, THC alone was associated with 
increased sleepiness 30 minutes after waking, and decreased latencies to early morning 
sleep (Nicholson et al., 2004). 
3.6.10. Genetic vulnerability to the effects of cannabis 
Hindocha et al. (2019) analysed the effects of cannabinoids on addiction 
endophenotypes. The study (n=48) found that carriers of the CNR1 rs1049353 GG 
genotype reported decreased desire to smoke a joint after both vaporised THC (8mg), 
and vaporised THC (8mg) with vaporised CBD (16mg) when compared to placebo. 
Those with the A allele did not experience this reduction. There was no difference 
between THC with or without CBD. Those with the FAAH rs324420 genotype CC 
had lower attentional bias to appetitive cues following THC only when compared to A 
carriers. By contrast, CC and A carriers did differ on attentional bias following 
THC+CBD. These findings suggest that the ability of CBD to influence the effects of 
THC may differ according to variation in endocannabinoid system genetics. 
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4. Discussion 
In the first systematic review of how CBD influences the acute effects of THC, 23 
eligible papers were identified reporting on 16 studies, including a total of 466 
participants. All studies employed experimental designs with adequate control 
conditions, enabling comparison of the acute effects of THC with those of a matched 
dose of THC combined with CBD. The risk of bias across within and across studies 
was typically low. 
When taken together, these results suggest that CBD may moderate some of the effects 
of THC, most commonly resulting in a reduction in its acute effects. However, the 
moderating effect of CBD was not consistent across all studies. There was some 
disparity in findings, and although the direction of associations was consistent in many 
studies associations did not reach statistical significance in all studies. There was also 
considerable heterogeneity in the interventions used across studies, including different 
routes of administration (oral, sublingual, smoked, vaporised, mixed with food, or 
made into a drink), doses of THC and CBD, and the ratio of THC to CBD. No 
consistent pattern of effects across these factors was found, consequently, it was not 
possible to determine whether there is a dose-response relationship influencing how 
CBD moderates the effects of THC. Several studies included an oral dose of CBD 
(5.4mg-800mg). As oral CBD has been shown to have low bioavailability (13-19%; 
Mechoulam, Parker, & Gallily, 2002) the findings from studies administering low 
doses of oral CBD should be interpreted with caution. Additionally, other factors may 
have influenced the effects of cannabinoids within studies and this may explain why 
several studies reported large variability in effects across participants. For example, 
cannabis use history, including the potency and frequency of previous cannabis used 
(Curran et al., 2002; Curran et al., 2018; D’Souza et al., 2008; Desrosiers, 2015), 
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psychosis-proneness (Mason et al., 2009), gender (Cooper & Haney, 2014; Klumpers 
et al., 2012) and genetic factors (Hindocha et al., 2019; Morgan, Freeman, Powell, & 
Curran, 2016) can influence the acute effects of cannabinoids. The majority of studies 
did not assess for these issues which, alongside some very small sample sizes, may 
have contributed to variability in findings. It is recommended that future research 
should take these factors into account. 
4.1. Pharmacokinetic and pharmacodynamics effects  
The results obtained in this review show mixed findings and it is not clear how CBD 
influences the way THC is metabolised. While two studies showed that combining 
CBD with THC may lead to an increased peak plasma of THC (Arkell et al., 2019; 
Nadulski et al., 2005) another showed that when CBD was combined with THC the 
time to reach peak plasma concentrations was delayed (Guy & Robson, 2003). Four 
studies showed non-significant findings when investigating the pharmacokinetic 
interactions between THC and CBD (Bhattacharyya et al., 2010; Englund et al., 2013; 
Hollister & Gillespie, 1975; Hunt et al., 1981). In animal studies (Paton & Pertwee, 
1972), CBD has been found to inhibit the metabolism of THC and potentially other 
drugs when administered together. There was some indication that gender may 
contribute to differences in metabolism of cannabinoids, as Roser et al. (2009) reported 
higher levels of 11-OH-THC and THC-COOH in women compared to men following 
THC with CBD, but not following THC alone, which is consistent with some evidence 
showing that women experience more intense subjective effects than men (Cooper & 
Haney, 2014; Haney et al., 2016). However, most studies in this review were small 
and did not report any significant differences in the pharmacokinetic profile of THC 
when it was combined with CBD. More extensive studies are needed to investigate 
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these effects, particularly because there seems to be substantial variability between 
participants.  
In terms of the pharmacodynamic profile, across studies, THC with and 
without CBD generally increased pulse rate. Outcomes on blood pressure were mixed, 
with two studies reporting that CBD reduced the effect of THC on diastolic and 
systolic blood pressure respectively. A recent study of a single dose of CBD (600mg) 
alone showed that it increases heart rate but reduces systolic blood pressure (Jadoon, 
Tan, & O'Sullivan, 2017). These effects may be a consideration for prescribing 
clinicians and as well as recreational users of the drug. 
4.2. Subjective intoxication 
Participants predominantly experienced the subjective intoxicating effects of THC and 
THC combined with CBD similarly. These findings suggest that co-administration of 
THC and CBD may not reduce the desired effects of cannabis (Curran & Morgan, 
2014).  
4.3. Anxiety and psychosis-like experiences  
Three studies included in this review showed that significantly fewer participants 
experienced extreme feelings of anxiety and psychotic-like effects when THC was co-
administered with CBD. A recent study showed that the therapeutic properties of CBD 
within specific prefrontal brain regions in rats might be present only during 
pathologically aberrant states induced by THC (Szkudlarek et al., 2019). A mechanism 
whereby CBD only regulates THC when it has extreme effects may explain findings 
where CBD reduced clinically significant increases in psychosis-like effects, but not 
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increases in these experiences overall (Englund et al., 2013). This may be an important 
consideration for future research, as previous studies may have excluded participants 
at risk of adverse effects of cannabis (such as acute psychotic symptoms) due to 
concerns about safety. However, the moderating effects of CBD may only be apparent 
in those who experience more severe responses to THC.   
4.4. Cognitive effects  
While some studies found that CBD was protective against the acute memory-
impairing effects of THC on tasks which tapped episodic memory and working 
memory, findings were not consistent. Schoeler and Bhattacharyya (2013) suggested 
that cannabis with higher doses of THC and lower CBD content produces robust acute 
memory deficits and that other factors may also contribute (e.g. tolerance, heavy early 
use). Regarding the specific components of memory that are affected, the studies 
included report outcomes for the number of items recalled correctly, consistent with 
an impairment in the encoding of episodic memories (Ballard, Gallo, & de Wit, 2012, 
2013). However, it is not clear whether these effects are also present for the retrieval 
of episodic memories which can be measured by comparing the recall of false 
intrusions (Doss, Weafer, Ruiz, Gallo, & De Wit, 2018). Evidence suggests that THC 
impairs encoding but not retrieval of episodic memory (Ranganathan et al., 2017), but 
the specific effects of CBD on encoding versus retrieval are currently unclear.  
Collectively, studies included in the current review which investigated effects on 
memory included a wide range of doses and routes of administration of both THC and 
CBD, and no clear pattern of results emerged.  
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One study found that verbal fluency was enhanced when vaporised THC was 
combined with CBD but there was no difference in verbal fluency performance 
between vaporised THC alone and placebo (Morgan et al., 2018). However, a previous 
study has shown that oral THC alone can dose-dependently enhance verbal fluency 
(Curran et al., 2002) while another study found that vaporized cannabis impaired 
verbal fluency (Kowal et al., 2015). This suggests that the effects of THC on verbal 
fluency are inconsistent, and may be moderated by other factors in addition to CBD. 
There was some evidence to suggest that CBD may influence the effects of 
THC on emotion and reward processing. When combined with THC, CBD attenuated 
impairments associated with THC (Hindocha et al., 2015; Lawn et al., 2016). These 
findings, however, come from only two studies. CBD did not reduce the impairments 
of THC across a range of psychomotor tasks (such as standing steadiness) in two 
studies (Bird et al., 1980; Dalton et al., 1976). One study found differences in finger 
tapping, where THC with CBD, but not THC alone, impaired performance on a task 
which is found to be related to impairments seen in schizophrenia (Roser et al., 2009). 
4.5. Genetics 
There was also evidence from two studies that genetic variants of the CNR1 gene may 
also influence the relationship between CBD and THC where the effects of the drugs 
alone and in combination depend on individual endocannabinoid system genetics 
(Hindocha et al., 2019; Stadelmann et al., 2011). Variations of the CNR1 gene may 
differentially alter sensitivity to the acute effects of cannabinoids on P300 generation 
(Stadelmann et al., 2011). Hindocha et al. (2019) found endocannabinoid system 
genetics may influence vulnerability to satiety, attentional bias towards appetitive cues 
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and craving which suggests that these differences may influence markers of 
vulnerability to cannabis use disorders.  
4.6. The role of CBD in harm reduction  
Although some studies reported that CBD may reduce the potentially harmful effects 
of cannabis, evidence suggests that combining THC with CBD may not necessarily 
reduce the desired intoxicating effects of the drug. More research is needed to fully 
elucidate how CBD influences the effects of THC. This is a complex issue as CBD has 
multiple mechanisms of action that may interact with THC to determine the health 
effects of the drug. For example, CBD may act to reduce some acute effects of THC 
through negative allosteric modulation of the CBR1 receptor (Hayakawa et al., 2008; 
Laprairie et al., 2015). There is however, also some evidence that CBD may increase 
plasma concentrations of THC (Arkell et al., 2019; Nadulski et al., 2005). The extent 
to which CBD acts via contrasting mechanisms such as these within and across 
individuals could account for the mixed and sometimes opposing effects of CBD 
reported in the literature to date. Further research should focus on establishing 
standardised methods for investigating these effects. One option might be for future 
research to focus on administration routes and doses which have the most ecological 
validity (such as vaporised or smoked cannabis, or sublingual methods for medicinal 
use). It may be helpful to establish standardised units of measurement of THC and 
CBD in cannabis to allow for more meaningful comparisons to be made between 
studies (T. P.  Freeman & Lorenzetti, in press). Further evidence is needed to 
strengthen the evidence base on how CBD influences the effects of THC, and to 
establish dose-response. As policymakers aim to guide regulation strategies and 
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educate consumers on how to minimise the risks of cannabis use, this is an important 
issue for future research.  
4.7. Strengths and limitations   
This review followed PRISMA guidelines for conducting and reporting 
systematic reviews (Higgins & Green, 2008; Liberati et al., 2009). Two independent 
raters were used for both searches and data extraction. This study used the Cochrane 
risk of bias tool (Higgins et al., 2016) to evaluate methodological criteria. This is the 
first systematic review to assess outcomes for human studies evaluating the 
moderating effects of CBD on the acute effects of THC. This review aimed to provide 
a narrative synthesis of a large variety of outcomes using a wide range of measures. 
To give a comprehensive picture of findings, where possible this review has 
incorporated all outcomes reported where THC with and without CBD were compared. 
In order to directly assess the acute effects of THC with and without CBD, it was 
necessary only to include studies that directly compared a matched dose and route of 
administration of THC with and without CBD. Therefore, repeated dosing studies and 
studies which looked at a range of administration methods were excluded. Cannabis 
contains over a hundred cannabinoids (such as cannabinol and 
tetrahydrocannabivarin). Similarly, there are more than a hundred terpenoids and some 
of these have the potential to moderate the effects and interactions of cannabinoids 
(Russo, 2011). Further research is needed to investigate how terpenoids and 
cannabinoids other than THC and CBD influence the effects of cannabis in humans.   
Methodological issues with the identified studies included: limited information about 
how withdrawals were managed; inadequate description or randomisation; treatment 
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allocation blinding and information about whether order effects were accounted for in 
statistical analyses. An additional limitation in some studies is that they included very 
small sample sizes. Although rigorous experimental designs which use repeated 
measures may afford higher statistical power, some studies may have nevertheless 
been underpowered when taking into account the effect sizes reported (Machin, 
Campbell, Tan, & Tan, 2018). Not all studies accounted for multiple analyses in their 
statistical analysis plan. Correlations for treatment response across conditions for 
individual participants was not considered in the analysis plan of several studies, which 
may have reduced power in crossover studies (Sedgwick, 2015).  
4.8. Conclusions  
The cannabis plant contains more than a hundred different cannabinoids and many of 
these may interact to determine the drug’s effects. At present, there is some evidence 
to suggest that CBD may reduce some of the effects of THC. However, significant 
variability was reported in the effects of these compounds both between studies and 
across individuals within studies. Further research is needed to investigate how CBD 
interacts with THC across a range of doses and routes of administration to gain further 
insight into how it might influence the benefits and harms of THC. 
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Appendix A. PRISMA Checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  8 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
9 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
9 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
9, 10 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
11 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated.  
11, 54 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
11 
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Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
11 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
11 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data synthesis.  
12 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  12 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
25 
Section/topic  # Checklist item  Reported 
on page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
12 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
NA 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
12 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
13-22 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  24 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
15-22 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  25-38 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  24 
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Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
NA 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
39-44 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
45 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
46 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
1 
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Appendix B. Review Protocol 
How does cannabidiol (CBD) influence the acute effects of delta-9- 
tetrahydrocannabinol (Δ9-THC) in humans? A systematic review 
Abigail Freeman, Rachel Lees, Katherine Petrilli, Rob Saunders, Chandni Hindocha, Claire Mokrysz, 
Tom Freeman, Valerie Curran 
Citation 
Abigail Freeman, Rachel Lees, Katherine Petrilli, Rob Saunders, Chandni Hindocha, Claire 
Mokrysz, Tom Freeman, Valerie Curran. How does cannabidiol (CBD) influence the acute 
effects of delta-9- tetrahydrocannabinol (Δ9-THC) in humans? A systematic review. 
PROSPERO 2019 CRD42019126994 Available 
from: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019126994 
 
Review question 
How does CBD influence the acute effects of Δ9-THC? 
 
Searches 
We will search the following electronic bibliographic databases: MEDLINE, EMBASE, 
PsycINFO, and CINAHL Plus. The search strategy will include only terms relating to or 
describing the intervention (Δ9-THC and CBD). The terms will be combined with the Ovid filter 
for human studies and studies published in English. The search terms will be adapted for use 
with other bibliographic databases in combination with database-specific filters for human 
trials and peer-reviewed articles, where these are available. 
There will be no date restrictions. The searches will be re-run just before the final synthesis 
and further studies retrieved for inclusion. Papers must be published in English. 
 
Types of study to be included 
Inclusion criteria: We will include human studies with an experimental design which include 
random allocation to (i) a fixed dose of THC (THC), and (ii) the same fixed dose of THC 
administered with CBD (THC+CBD). Participants must be compared to a matched control 
group, or act as their own controls (crossover design). The included papers must be peer-
reviewed. 
 
Exclusion criteria: 
Conference extracts or abstracts, theses, reviews, supplements, editorial reports, 
correspondence, non-peer reviewed material e.g., books extracts, notes, and letters. 
Animal studies. 
 
Condition or domain being studied 
The acute administration of Δ9-THC and CBD in humans. 
 
Participants/population 
Inclusion: Human participants 
Exclusion: None 
 
Intervention(s), exposure(s) 
Studies must include both a) a condition or group in which delta-9-tetrahydrocannabinol (Δ9-
THC/ THC/tetrahydrocannabinol/dronabinol) is acutely administered under experimental 
conditions, and b) a matched condition or group where the same dose of Δ9-THC is acutely 
administered together with cannabidiol (CBD). 
Comparator(s)/control 
Placebo or a control condition where there is no drug administered, for example, a pre-drug 
measurement or baseline measurement. This is necessary to evaluate the acute effects of 
THC. 
 
Context 
Human laboratory studies which include healthy or clinical populations. 
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Main outcome(s) 
Establishing how CBD influences the acute effects of THC in humans (change in THC-induced 
effect when THC is administered with CBD). 
 
Additional outcome(s) 
None. 
 
Data extraction (selection and coding) 
Titles and/or abstracts of studies retrieved using the search strategy and those from additional 
sources will be screened independently by two reviewers to identify studies that potentially 
meet the inclusion criteria outlined above. The full text of these potentially eligible studies will 
be retrieved and independently assessed for eligibility by two review team members. Any 
disagreement between them over the eligibility of particular studies will be resolved through 
discussion with a third reviewer. 
A standardised, pre-piloted form will be used to extract data from the included studies for 
assessment of study quality and evidence synthesis. Extracted information will include: study 
setting; study population and details of the dose and route of administration for THC and CBD, 
THC:CBD ratio; study methodology; recruitment and study completion rates; outcomes and 
times of measurement; information for assessment of the risk of bias. Two reviewers will 
extract data, discrepancies will be identified and resolved through discussion with a third 
reviewer where necessary. A subset of the extracted data will be randomly checked by a third 
reviewer. 
 
Risk of bias (quality) assessment 
Two reviewers will independently assess the risk of bias in included studies by considering 
the criteria set out by the Cochrane’s risk of bias (RoB2) assessment tool as appropriate for 
the study design. Disagreements between the reviewers over the risk of bias in particular 
studies will be resolved by discussion, with involvement of a third review author where 
necessary. 
 
Strategy for data synthesis 
We will provide a narrative synthesis of the findings from the included studies, structured 
around the type of intervention, type of outcome and intervention content. We will provide 
summaries of intervention effects for each study. From initial scoping of the existing literature, 
we anticipate that the opportunity for meta-analysis may be limited because of the range of 
different outcomes measured across studies. 
 
Analysis of subgroups or subsets 
It is not expected that the studies will be reviewed separately for different groups. However, 
outcomes for different drug doses may be presented separately. 
 
Contact details for further information 
Abigail Freeman 
abigail.freeman@ucl.ac.uk 
 
Organisational affiliation of the review 
University College London 
 
Review team members and their organisational affiliations 
Ms Abigail Freeman. University College London 
Miss Rachel Lees. University College London, London, UK 
Miss Katherine Petrilli. University College London, London, UK 
Dr Rob Saunders. University College London, London, UK 
Dr Chandni Hindocha. University College London, London, UK 
Dr Claire Mokrysz. University College London, London, UK 
Dr Tom Freeman. University of Bath, Bath, UK 
Professor Valerie Curran. University College London, London, UK 
 
Type and method of review 
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Narrative synthesis, Systematic review 
Anticipated or actual start date 
24 February 2019 
Anticipated completion date 
01 October 2019 
Funding sources/sponsors 
None 
Conflicts of interest 
None  
Language 
English 
Country 
England 
Stage of review 
Review Ongoing 
Subject index terms status 
Subject indexing assigned by CRD 
Subject index terms 
Cannabidiol; Dronabinol; Humans 
Date of registration in PROSPERO 
18 March 2019 
Date of publication of this version 
18 March 2019 
Details of any existing review of the same topic by the same authors 
None  
 
Stage of review at time of this submission 
Stage Started Completed 
Preliminary searches Yes No 
Piloting of the study selection process No No 
Formal screening of search results against eligibility criteria No No 
Data extraction No No 
Risk of bias (quality) assessment No No 
Data analysis No No 
 
Versions 
18 March 2019 
PROSPERO 
This information has been provided by the named contact for this review. CRD has accepted this 
information in good faith and registered the review in PROSPERO. The registrant confirms that the 
information supplied for this submission is accurate and complete. CRD bears no responsibility or 
liability for the content of this registration record, any associated files or external websites. 
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Appendix C. Search strategy 
Search Strategy: Embase 1974 to 2019 February 27  
 
# Searches Results 
1 cannabis*.tw. 19528 
2 THC*.tw. 12293 
3 tetrahydrocannabinol*.tw. 7913 
4 delta-9-tetrahydrocannabinol*.tw. 1913 
5 dronabinol*.tw. 490 
6 Dronabinol/ 7043 
7 Dronabinol/ 30687 
8 cbd*.tw. 12647 
9 Cannabidiol*.tw. 2835 
10 Cannabidiol/ 3660 
11 marijuana*.tw. 14832 
12 8 or 9 or 10 14970 
13 
(books or review or erratum or note or editorial or letter or "short survey" or tombstone 
or "conference paper" or "conference abstract").pt. 
9350415 
14 tetrahydrocannabinol/ or dronabinol/ or cannabis/ 38377 
15 1 or 2 or 3 or 4 or 5 or 6 or 7 or 11 or 14 55349 
16 12 and 15 3241 
17 16 not 13 1820 
18 limit 17 to (human and English language) 721 
 
Search Strategy: Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed 
Citations and Daily 1946 to February 27, 2019  
 
# Searches Results 
1 cannabis*.tw. 14086 
2 THC*.tw. 8799 
3 tetrahydrocannabinol*.tw. 6408 
4 delta-9-tetrahydrocannabinol*.tw. 3234 
5 dronabinol*.tw. 308 
6 Dronabinol/ 6606 
7 Cannabis/ 8197 
8 cbd*.tw. 7736 
9 Cannabidiol*.tw. 2052 
10 Cannabidiol/ 1255 
11 marijuana*.tw. 11743 
12 8 or 9 or 10 8769 
13 
(books or review or erratum or note or editorial or letter or "short survey" or tombstone 
or "conference paper" or "conference abstract").pt. 
3959425 
14 tetrahydrocannabinol/ or dronabinol/ or cannabis/ 13133 
15 1 or 2 or 3 or 4 or 5 or 6 or 7 or 11 or 14 35691 
16 12 and 15 1765 
17 16 not 13 1399 
18 limit 17 to (human and English language) 535 
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Search Strategy:  PsycINFO 1806 to February Week 1 2019  
# Searches Results 
1 cannabis*.tw. 9350 
2 THC*.tw. 2179 
3 tetrahydrocannabinol*.tw. 2240 
4 delta-9-tetrahydrocannabinol*.tw. 892 
5 dronabinol*.tw. 95 
6 cbd*.tw. 846 
7 Cannabidiol*.tw. 555 
8 marijuana*.tw. 9477 
9 
(books or review or erratum or note or editorial or letter or "short survey" or tombstone 
or "conference paper" or "conference abstract").pt. 
0 
10 exp CANNABIS/ 7501 
11 exp MARIJUANA/ 2902 
12 exp Marijuana/ or exp Tetrahydrocannabinol/ or exp Cannabis/ 8462 
13 1 or 2 or 3 or 4 or 5 or 8 or 10 or 11 or 12 19213 
14 6 or 7 1031 
15 13 and 14 459 
16 15 not 9 459 
17 limit 16 to (human and English language) 250 
CINHAL Plus up to February Week 1 2019  
(MH "cannabis" or “cannabis” or “THC” or “tetrahydrocannabinol” or “delta-9-
tetrahydrocannabinol or “dronabinol” ) AND ( cbd or “cannabidiol" )  
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Appendix D. Data extraction form 
Table D.1. Study Characteristic extraction template  
Reviewer: Notes     
Study ID  
Experimental design? Type of study: (e.g. placebo-controlled, double-blind, parallel, 
crossover, non-RCT) 
 
Random allocation? How as it randomised, Unit of randomisation (by individuals, 
groups) 
 
Placebo or a control condition where measurement is taken with no drug 
administered?  
 
Types of intervention: (i) a fixed dose of THC, and (ii) the same fixed dose of THC 
administered with CBD (THC+CBD)? Any other interventions? 
 
Assessment of acute effects: i.e. single dose or multiple doses in a single session  
Include or Exclude  
Reason: repeated dosing study, no baseline measurement, No THC+CBD or meets 
inclusion criteria - list  
 
Do not proceed if excluded.  
Aim of study as stated   
Population description: For example, healthy current users, healthy ever users, 
clinical population, CUD  
 
Abstinence: How many hours drug-free before dosing?  
Inclusion criteria/Exclusion criteria  
Number of participants  
If parallel Include information for each group (i.e. intervention and controls) under 
study 
 
Withdrawals and exclusions  
Were there any significant baseline imbalances?  
Were patients who entered the study adequately accounted for?   
Age; range, median mean, SD   
Sex (M, F)  
Race/Ethnicity  
Cannabis use status: current and historical   
Co-morbidities & other relevant demographics  
Intervention & control (route of admin, content, dose, schedule) For example, 
smoked THC 8mg; oral CBD 800mg 
 
Dosing schedule: For example, CBD administered one hour before THC dose  
Sample size calculation: What assumptions were made?  Were these assumptions 
appropriate? 
 
A potential conflict of interest from funding? Y / N / unclear  
Types of outcome measures: e.g. fMRI, psychological, pharmacokinetic  
Outcomes comparing THC vs THC+CBD:  1/2 short sentences for each outcome   
Key conclusions of the study  
Notes  
Limitations/strengths   
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Appendix E. Studies excluded in full-text search 
Table E. 1. Study characteristics for inclusion criteria for each study excluded in a full-text search  
Study Design Randomisation  
Placebo or 
baseline Intervention Treatment schedule 
Reason for 
exclusion 
Agurell et al. 
(1981) 
Crossover 
study 
Balanced crossover 
sequence 
No placebo or 
baseline 
measurement 
Oral 20 mg of THC and placebo; 
oral 20 mg of THC, and oral 40 
mg of CBD; oral 20 mg of THC 
and oral 40 mg of CBN. 
Single dose, weekly 
interval 
No baseline 
measurement pre-
THC 
Babalonis et 
al. (2017) 
Double-blind, 
crossover 
study 
Random allocation Placebo 
Oral cannabidiol (0, 200, 400, 800 
mg) alone and in combination 
with smoked marijuana 0.01%; 
5.3–5.8% THC 
8 once-weekly 
outpatient sessions 
(7.5 h) 
No active 
THC+CBD 
condition 
Berman, 
Symonds, and 
Birch (2004) 
Double-blind,  
crossover 
study 
Randomly allocated 
to treatment order 
by a computer 
Placebo 
Oromucosal spray GW-1000-02: 
Sativex THC:CBD) 1:1 ratio; 
GW-2000-02 THC; placebo 
Baseline period of 2 
weeks, followed by 
three, 2-week 
treatment periods 
Repeated dosing 
study 
Brady et al. 
(2004) 
Crossover 
study 
NA Open label  
Sublingual spray THC (2.5mg); 
THC (2.5mg) +CBD (2.5mg)  
Repeated dosing 16 
weeks  
Repeated dosing 
study  
Efron and 
Freeman 
(2018) 
NA NA NA NA NA Commentary 
Guy and Flint 
(2003) 
Partially 
double-blind, 
crossover 
study 
Partially 
randomised, 
Placebo 
Sublingual drops placebo; THC 
(20mg); THC (20mg) + CBD 
(20mg) 
Single dose 
THC+CBD 
condition is open 
label  
Guy and 
Robson (2004) 
Four-way 
crossover 
study 
Randomised;  
Williams 
Square Design 
Open label 
Sublingual, buccally, oro-
pharyngenally, or oral THC 10mg 
+ CBD 10mg 
Single dose; 6 day 
washout 
No THC only 
comparator 
Ilan, Gevins, 
Coleman, 
ElSohly, and 
de Wit (2005) 
Double-blind, 
crossover 
study 
Randomised Placebo 
Smoked Placebo; smoked  THC 
1.91%, Low CBC 0.6% and Low 
CBD 0.2%; smoked THC 2.86%, 
Low CBC 0.1% and High CBD 
Single dose, weekly 
interval 
Not comparable 
matched doses for 
THC in both THC 
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1.0%; smoked THC1.88%, Low 
CBC 0.1% and High CBD 1.52%; 
smoked THC 3.09%, High CBC 
0.5% and Low CBD 0.08% 
and THC+CBD 
condition  
Johnson et al. 
(2010) 
Double-blind, 
parallel  
study 
Randomised Placebo 
Oromucosal spray THC (2.7mg) 
THC (2.7mg) + CBD (2.5mg) 
extract and placebo 
Repeated dosing over 
2 weeks 
Repeated dosing 
study  
Karniol and 
Carlini (1974) 
NA NA NA NA NA Unable to access 
Karschner 
2011 
Karschner et 
al. (2011) 
Double-blind, 
crossover 
study 
Randomised Placebo 
Oral THC (5mg), oral THC 
(15mg); oromucosal spray THC 
(5.4mg) + CBD (5mg), spray 
THC (16.2mg) + CBD (15.0mg) 
or placebo 
Single dose, 5 days 
washout 
Different routes of 
administration 
Karschner et 
al. (2011) 
Double-blind, 
crossover 
study 
Randomised Placebo 
Oral THC (5mg), oral THC 
(15mg); oromucosal spray THC 
(5.4mg) + CBD (5mg), spray 
THC (16.2mg) + CBD (15.0mg) 
or placebo 
Single dose 
Different routes of 
administration 
Lee et al. 
(2013) 
Double-blind, 
crossover 
study 
Randomised Placebo 
Oral THC (5mg), oral THC 
(15mg); oromucosal spray THC 
(5.4mg) + CBD (5mg), spray 
THC (16.2mg) + CBD (15.0mg) 
or placebo 
Single dose 
Different routes of 
administration 
Leweke et al. 
(2000) 
Double-blind, 
crossover 
study   
 
No Baseline 
Oral placebo+ nabilone (1mg); 
nabilone (1mg)  +CBD (200mg); 
CBD (200mg) + placebo 
Single dose Not randomised  
Notcutt et al. 
(2004) 
34 ‘n of 1’ 
studies 
Randomised Placebo 
Sublingual spray THC (2.5mg); 
THC (2.5mg); THC (2.5mg) + 
CBD (2.5mg); placebo 
12 weeks repeated 
dosing 
Repeated dosing 
study 
Perez-Reyes et 
al. (1973) 
Crossover 
study 
Randomised Placebo 
THC (0.53mg/kg); CBD 
(0.27mg/kg); CBN (0.27mg/kg); 
placebo 
Single dose  
No THC+CBD 
condition  
  
 
5
9
 
Perry, Ton, 
and Allan 
(2018) 
NA NA NA NA NA Review 
Solowij et al. 
(2019) 
Crossover 
study 
Randomised  Placebo 
THC 8 + CBD 4 mg; THC 8 mg, 
THC 12 + CBD 400; CBD 
400mg, Placebo 
Single dose 
No comparison 
between THC 8 + 
CBD 4 mg; THC 8 
mg alone; only 
linear function 
across all THC 
conditions 
Strasser et al. 
(2006) 
Double-blind, 
placebo-
controlled 
study 
Randomly assigned 
(2:2:1) 
Placebo 
Oral cannabis extract 
(standardized for 2.5 mg THC and 
1 mg cannabidiol); THC (2.5 
mg); placebo 
Twice daily for 6 
weeks 
Repeated dosing 
study 
Schoedel et al. 
(2011) 
Double-blind, 
crossover 
study 
Randomised 
Placebo, and 
baseline 
Oromucosal spray THC (10.8 mg) 
+ CBD (10 mg); THC (21.6 mg) 
+  CBD (20mg); THC (43.2 mg) 
+ CBD (40 mg); oral dronabinol 
(20 mg); dronabinol (40 mg),  
placebo 
Single dose, 2 day 
washout 
Not matched 
control/dose 
Valle et al. 
(2015) 
Double-blind, 
crossover 
study 
Randomised Placebo 
Sublingual THC (7.5mg); CBD 
(7,5mg), THC (7.5mg) + CBD 
(7.5mg) 
Single dose Abstract only 
Wade et al. 
(2003) 
Single-patient, 
crossover 
study 
Randomised Placebo 
Sublingual spray THC (2.5mg); 
CBD (2.5mg); THC (2.5mg) + 
CBD(2.5mg); placebo 
Two week repeated 
dosing 
Repeated dosing 
study 
Wade, 
Makela, 
Robson, 
House, and 
Bateman 
(2004) 
Double-blind, 
parallel study 
Randomised Placebo 
Sublingual spray THC (2.5mg); 
CBD (2.5mg); THC (2.5mg) + 
CBD(2.5mg); placebo 
Six week repeated 
dosing 
Repeated dosing 
study  1 
Yuan et al. 
(2017) 
Case report NA NA 3-4 joints a day THC (18.6%)  Repeated dosing  Case report 
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Appendix F. PRISMA flowchart 
Figure 1. PRISMA flow diagram (Moher, Liberati, Tetzlaff, Altman, & Group, 2009) 
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Records identified through 
database searching (n = 1808) 
 EMBASE: 721 
PsycINFO: 250 
MEDLINE(R): 535 
CINAHL: 302 
Additional records 
identified through 
other sources n = 4 
Records after duplicates removed 
n = 1207 
Titles and Abstracts 
screened 
n = 1211 
Records excluded 
n = 1164 
Full-text articles 
assessed for eligibility 
n = 47 
Full-text articles excluded n=24 
Repeated dosing study n = 7 
No baseline or pure placebo n = 1 
No THC+CBD condition n = 2 
No THC only condition n = 1 
No matched dose THC n = 2 
No direct comparison between 
matched dose THC alone and 
combination with CBD treatment n=1 
Different route of administration n=3 
Not randomised n=1 
Open-label n=1 
Unable to access n=1 
Commentary n= 1 
Abstract n=1 
Case report n=1 
Review n= 1 
Studies included in a 
narrative synthesis  
k = 16 from n= 23 
articles  
Records excluded 
n = 601 
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Appendix G. Risk of bias assessment for each study 
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Arkell et al. (2019) 
      
 
Bhattacharyya et al. (2010)  
      
 
Bird et al. (1980)b 
     
 
 
 
Dalton et al. (1976)  
      
 
Dalton et al. (1976)  
      
 
Englund et al. (2013)  
      
 
Guy and Robson (2003)  
      
 
Haney et al. (2016)c 
      
  
Hindocha et al. (2015); Morgan et al. (2018) 
      
 
Hollister and Gillespie (1975)d 
 
 
     
 
Hunt et al. (1981)  
      
  
Karniol et al. (1974) 
      
T. P. Freeman, Pope, et al. (2018); Lawn et al. (2016); Wall et 
al. (2019)  
      
Juckel et al. (2007); Nadulski et al. (2005); Roser et al. 
(2009); Roser et al. (2008); Stadelmann et al. (2011)e 
      
 
Nicholson et al. (2004)  
      
 
Zuardi et al. (1982)f 
      
Notes.  
a. Studies were assessed for both potential bias arising from intevention assignment and assessment 
b. Whether groups were balanced, and how many per group is not reported, the total number of particpants 
does not devide equally between the groups  
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c. 31/50 participants completed raising some concerns about potential bias.  
d. No indication of blinding, study states randomisation process so at least participant concealment is 
assumed by some concern noted. Study does not report statistics.  
e. Study had fewer than 90-95% of particpants who were randomised complete the intervention 
f. Some concerns about the randomisation and blinding of the study as this is not indicated in the article it 
seems reasonable to assume that as it was placebo cotrolled it would also be blinded. Treatments allocated 
in a different order but so each followed eachother, so its possible the experimeter would have been able 
to guess the drug allocation.  
 
                  No issues  
 
                  Some concerns  
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Appendix H. Psychological effects of drug action scale 
The psychological effects of drug action were graded from 0 to 4, according to the 
subjective report of at least three symptoms in a grade: 
Grade 0: nothing or slight anxiety. 
Grade 1: slight feeling of well-being; feeling of lightness; paraesthesia in extremities; 
slight difficulty in concentration; dizziness; somnolence; cold hands and sweating. 
Grade 2: definite feeling of well-being; euphoria; colours are brighter; intense 
paraesthesia; uninterested by the surroundings; some difficulty in reporting feelings; 
sometimes slight sensation of fear; intense difficulty in concentration. 
Grade 3: marked sensation of euphoria intercalated with moments of apprehension; 
intense introspection with resistance to describing feelings; sensation of being 
watched; sounds are clearer and colours are brighter; laughing without reason; 
concentration almost impossible due to the rapid flow of ideas; extremities very heavy; 
unable to visualize intact objects with eyes closed (e.g. watch seen without numbers 
or hands). 
Grade 4: feelings of well-being followed later by panic; intense sensation of being 
watched; coherent thoughts impossible due to the rapid flow of ideas; in general, 
subject knows what is happening, but loses the knowledge from time to time and panic 
starts; cenesthesia; striking visual hallucinations. 
Taken from: Carlini, Karniol, Renault, and Schuster (1974) 
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